PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17953471-3	2007	Repaglinide is an insulin secretagogue that lowers blood glucose levels in patients with T2DM.	repaglinide	0-11	insulin	Homo sapiens	18-25
16513447-0	2006	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.	repaglinide	129-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-118
17253883-8	2007	In addition to CYP3A4, repaglinide is metabolised via CYP2C8, while nateglinide metabolism also involves CYP2C9.	repaglinide	23-34	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	54-60
17253883-15	2007	The most impressive pharmacokinetic interaction was reported with combined administration of gemfibrozil (a strong CYP2C8 inhibitor) and repaglinide (8-fold increase in repaglinide AUC).	repaglinide	137-148	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	115-121
16796707-2	2006	A recent study showed that SLCO1B1 (which codes the OATP1B1 gene, also known as OATP-C, OATP2) is a major determinant which markedly affects the pharmacokinetics of repaglinide.	repaglinide	165-176	solute carrier organic anion transporter family member 1B1	Homo sapiens	27-34
16796707-2	2006	A recent study showed that SLCO1B1 (which codes the OATP1B1 gene, also known as OATP-C, OATP2) is a major determinant which markedly affects the pharmacokinetics of repaglinide.	repaglinide	165-176	solute carrier organic anion transporter family member 1B1	Homo sapiens	52-59
16796707-2	2006	A recent study showed that SLCO1B1 (which codes the OATP1B1 gene, also known as OATP-C, OATP2) is a major determinant which markedly affects the pharmacokinetics of repaglinide.	repaglinide	165-176	solute carrier organic anion transporter family member 1B1	Homo sapiens	80-86
16796707-2	2006	A recent study showed that SLCO1B1 (which codes the OATP1B1 gene, also known as OATP-C, OATP2) is a major determinant which markedly affects the pharmacokinetics of repaglinide.	repaglinide	165-176	solute carrier organic anion transporter family member 1B1	Homo sapiens	88-93
16865362-0	2006	Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.	repaglinide	15-26	ATPase phospholipid transporting 8A2	Homo sapiens	90-93
16865362-2	2006	The insulinotrope repaglinide is successful in therapy, but has been reported to inhibit the recombinant K(ATP) channels of beta cells, cardiocytes and non-vascular smooth muscle cells with similar potencies, suggesting that the (patho-)physiological role of the cardiovascular K(ATP) channels may be overstated.	repaglinide	18-29	ATPase phospholipid transporting 8A2	Homo sapiens	107-110
16865362-2	2006	The insulinotrope repaglinide is successful in therapy, but has been reported to inhibit the recombinant K(ATP) channels of beta cells, cardiocytes and non-vascular smooth muscle cells with similar potencies, suggesting that the (patho-)physiological role of the cardiovascular K(ATP) channels may be overstated.	repaglinide	18-29	ATPase phospholipid transporting 8A2	Homo sapiens	280-283
16865362-3	2006	We therefore re-examined repaglinide"s potency at and affinity for the recombinant pancreatic, myocardial and vascular K(ATP) channels in comparison with glibenclamide.	repaglinide	25-36	ATPase phospholipid transporting 8A2	Homo sapiens	110-125
16865362-8	2006	CONCLUSIONS/INTERPRETATION: Repaglinide and glibenclamide show higher potency and efficacy in inhibiting the pancreatic than the cardiovascular K(ATP) channels, thus supporting their clinical use.	repaglinide	28-39	ATPase phospholipid transporting 8A2	Homo sapiens	146-149
17211567-0	2006	Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.	repaglinide	12-23	insulin	Homo sapiens	44-51
17211567-0	2006	Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.	repaglinide	12-23	insulin	Homo sapiens	127-134
17211567-1	2006	In this study, we investigated the effects of combining preprandial repaglinide to the insulin therapy for reducing the exogenous insulin requirements and serum HbA(1c) levels in type 2 diabetic patients whose blood glucose levels were previously regulated by multiple dose intensive insulin therapy.	repaglinide	68-79	insulin	Homo sapiens	130-137
17211567-1	2006	In this study, we investigated the effects of combining preprandial repaglinide to the insulin therapy for reducing the exogenous insulin requirements and serum HbA(1c) levels in type 2 diabetic patients whose blood glucose levels were previously regulated by multiple dose intensive insulin therapy.	repaglinide	68-79	insulin	Homo sapiens	130-137
17211567-9	2006	A significant reduction regarding exogenous insulin requirements and serum HbA(1c) levels were demonstrated in patients taking preprandial repaglinide (p<0.01).	repaglinide	139-150	insulin	Homo sapiens	44-51
16539642-1	2006	The purpose of this study was to investigate the use of the short-acting insulin secretion drug repaglinide in new-onset diabetes mellitus (NODM) after renal transplantation.	repaglinide	96-107	insulin	Homo sapiens	73-80
16513447-1	2006	BACKGROUND AND OBJECTIVE: The antidiabetic repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and CYP3A4.	repaglinide	43-54	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	73-98
16513447-1	2006	BACKGROUND AND OBJECTIVE: The antidiabetic repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and CYP3A4.	repaglinide	43-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109
16513447-12	2006	CONCLUSIONS: Telithromycin increases the plasma concentrations and blood glucose-lowering effect of repaglinide by inhibiting its CYP3A4-catalyzed biotransformation and may increase the risk of hypoglycemia.	repaglinide	100-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-136
16176562-0	2005	Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.	repaglinide	14-25	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	29-35
16447051-2	2006	Repaglinide, a meglitinide analogue antidiabetic, is metabolised by CYP2C8 and CYP3A4.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	68-74
16447051-2	2006	Repaglinide, a meglitinide analogue antidiabetic, is metabolised by CYP2C8 and CYP3A4.	repaglinide	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
16299161-9	2006	The results described have important implications for the mechanism of the clinical interaction reported between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone.	repaglinide	169-180	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	129-135
16176562-5	2005	At therapeutic repaglinide concentrations (<0.4 microM), CYP2C8 and CYP3A4 metabolised repaglinide at similar rates.	repaglinide	15-26	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	60-66
16433710-5	2006	RESULTS: Adenosine diphosphate (ADP)-induced platelet P-selectin expression increased post-meal in Type 2 diabetic patients both at baseline and after treatment with repaglinide and glibenclamide (P < 0.01 for all; repeated measures anova).	repaglinide	166-177	selectin P	Homo sapiens	54-64
16433710-6	2006	Repaglinide treatment reduced fasting ADP-induced P-selectin expression compared with baseline (P = 0.01), but did not influence meal-induced platelet hyper-reactivity (P = 0.32).	repaglinide	0-11	selectin P	Homo sapiens	50-60
16433710-8	2006	Plasma concentrations of VWF and ICAM-1 were elevated in patients with Type 2 diabetes compared with control subjects (P < 0.05 for both) and were reduced during treatment with repaglinide (P < 0.01 for both) but did not change during glibenclamide treatment.	repaglinide	180-191	von Willebrand factor	Homo sapiens	25-28
16433710-8	2006	Plasma concentrations of VWF and ICAM-1 were elevated in patients with Type 2 diabetes compared with control subjects (P < 0.05 for both) and were reduced during treatment with repaglinide (P < 0.01 for both) but did not change during glibenclamide treatment.	repaglinide	180-191	intercellular adhesion molecule 1	Homo sapiens	33-39
16475928-4	2006	Blockers of Kir6.2/SUR1 channels, e.g. glibenclamide and repaglinide stimulate release of insulin and are used for treatment of type 2 diabetes.	repaglinide	57-68	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	12-18
16475928-4	2006	Blockers of Kir6.2/SUR1 channels, e.g. glibenclamide and repaglinide stimulate release of insulin and are used for treatment of type 2 diabetes.	repaglinide	57-68	ATP binding cassette subfamily C member 8	Homo sapiens	19-23
16475928-4	2006	Blockers of Kir6.2/SUR1 channels, e.g. glibenclamide and repaglinide stimulate release of insulin and are used for treatment of type 2 diabetes.	repaglinide	57-68	insulin	Homo sapiens	90-97
16176562-5	2005	At therapeutic repaglinide concentrations (<0.4 microM), CYP2C8 and CYP3A4 metabolised repaglinide at similar rates.	repaglinide	90-101	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	60-66
16176562-5	2005	At therapeutic repaglinide concentrations (<0.4 microM), CYP2C8 and CYP3A4 metabolised repaglinide at similar rates.	repaglinide	90-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
16176562-9	2005	In conclusion, both CYP2C8 and CYP3A4 are important in the metabolism of therapeutic concentrations of repaglinide in vitro, but their predicted contributions in vivo are highly dependent on the scaling factor used.	repaglinide	103-114	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
16176562-9	2005	In conclusion, both CYP2C8 and CYP3A4 are important in the metabolism of therapeutic concentrations of repaglinide in vitro, but their predicted contributions in vivo are highly dependent on the scaling factor used.	repaglinide	103-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
16176562-0	2005	Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.	repaglinide	14-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
16176562-1	2005	Repaglinide is an antidiabetic drug metabolised by cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	51-76
16176562-1	2005	Repaglinide is an antidiabetic drug metabolised by cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes.	repaglinide	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
16176562-3	2005	We studied repaglinide metabolism using pooled human liver microsomes, recombinant CYP2C8 and recombinant CYP3A4 enzymes.	repaglinide	11-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
16142016-7	2005	Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).	repaglinide	182-193	insulin	Homo sapiens	16-23
16198658-1	2005	BACKGROUND AND OBJECTIVE: Repaglinide is an antidiabetic drug metabolized by cytochrome P450 (CYP) 2 C 8 and 3A4, and it appears to be a substrate of the hepatic uptake transporter organic anion transporting polypeptide 1B1 (OATP1B1).	repaglinide	26-37	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	77-104
16198658-1	2005	BACKGROUND AND OBJECTIVE: Repaglinide is an antidiabetic drug metabolized by cytochrome P450 (CYP) 2 C 8 and 3A4, and it appears to be a substrate of the hepatic uptake transporter organic anion transporting polypeptide 1B1 (OATP1B1).	repaglinide	26-37	solute carrier organic anion transporter family member 1B1	Homo sapiens	225-232
16198658-13	2005	The effect of cyclosporine on repaglinide AUC0-infinity was 42% lower in subjects with the SLCO1B1 521TC genotype than in subjects with the 521TT (reference) genotype (P=.047).	repaglinide	30-41	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
16198658-15	2005	CONCLUSIONS: Cyclosporine raised the plasma concentrations of repaglinide, probably by inhibiting its CYP3A4-catalyzed biotransformation and OATP1B1-mediated hepatic uptake.	repaglinide	62-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
16198658-15	2005	CONCLUSIONS: Cyclosporine raised the plasma concentrations of repaglinide, probably by inhibiting its CYP3A4-catalyzed biotransformation and OATP1B1-mediated hepatic uptake.	repaglinide	62-73	solute carrier organic anion transporter family member 1B1	Homo sapiens	141-148
16176204-0	2005	Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.	repaglinide	0-11	insulin	Homo sapiens	44-51
16176204-2	2005	The present study was undertaken to explore a possible influence of the oral prandial glucose regulator, repaglinide, on first-phase insulin secretion and high-frequency insulin pulsatility in Type 2 diabetes.	repaglinide	105-116	insulin	Homo sapiens	133-140
16176204-10	2005	In addition, glucose entrained insulin secretory burst mass and amplitude increased markedly (burst mass: repaglinide, 44.4 +/- 6.0 pmol/l/pulse vs. placebo, 31.4 +/- 3.3 pmol/l/pulse, P < 0.05; burst amplitude: repaglinide, 17.7 +/- 2.4 pmol/l/min vs. placebo, 12.6 +/- 1.3 pmol/l/min, P < 0.05) while basal insulin (non-pulsatile) secretion was unaltered.	repaglinide	106-117	insulin	Homo sapiens	31-38
16176204-10	2005	In addition, glucose entrained insulin secretory burst mass and amplitude increased markedly (burst mass: repaglinide, 44.4 +/- 6.0 pmol/l/pulse vs. placebo, 31.4 +/- 3.3 pmol/l/pulse, P < 0.05; burst amplitude: repaglinide, 17.7 +/- 2.4 pmol/l/min vs. placebo, 12.6 +/- 1.3 pmol/l/min, P < 0.05) while basal insulin (non-pulsatile) secretion was unaltered.	repaglinide	215-226	insulin	Homo sapiens	31-38
16176204-11	2005	After acute repaglinide exposure (0.5 mg) basal insulin secretion increased significantly (P < 0.05).	repaglinide	12-23	insulin	Homo sapiens	48-55
16176204-13	2005	CONCLUSION/INTERPRETATION: Repaglinide augments first-phase insulin secretion as well as high-frequency insulin secretory burst mass and amplitude during glucose entrainment in patients with Type 2 diabetes, while regularity of the insulin release process was unaltered.	repaglinide	27-38	insulin	Homo sapiens	60-67
15944840-3	2005	Catalase activity was significantly increased in diabetic liver (67.5+/-3.6 vs. 39.7+/-5.6 and 62.3+/-2.7 vs. 52.6+/-5.3 micromol H(2)O(2)/min/mg protein) and normalised by repaglinide (49.2+/-4.0 and 41.2+/-3.8 micromol H(2)O(2)/min/mg protein).	repaglinide	173-184	catalase	Oryctolagus cuniculus	0-8
16142016-4	2005	Lowering in plasma PAI-1 and PAP levels was significantly greater in repaglinide group.	repaglinide	69-80	serpin family E member 1	Homo sapiens	19-24
16142016-5	2005	Furthermore, repaglinide administration resulted in a significant decrease in fasting plasma free fatty acids, fibrinogen, thrombin-antithrombin complex and reaction product of malondialdehyde with thiobarbituric acid (TBARS) levels, in absence of significant difference in fasting plasma insulin levels.	repaglinide	13-24	fibrinogen beta chain	Homo sapiens	111-121
16142016-5	2005	Furthermore, repaglinide administration resulted in a significant decrease in fasting plasma free fatty acids, fibrinogen, thrombin-antithrombin complex and reaction product of malondialdehyde with thiobarbituric acid (TBARS) levels, in absence of significant difference in fasting plasma insulin levels.	repaglinide	13-24	coagulation factor II, thrombin	Homo sapiens	123-131
16142016-7	2005	Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).	repaglinide	182-193	insulin	Homo sapiens	250-257
16142016-5	2005	Furthermore, repaglinide administration resulted in a significant decrease in fasting plasma free fatty acids, fibrinogen, thrombin-antithrombin complex and reaction product of malondialdehyde with thiobarbituric acid (TBARS) levels, in absence of significant difference in fasting plasma insulin levels.	repaglinide	13-24	serpin family C member 1	Homo sapiens	132-144
16142016-5	2005	Furthermore, repaglinide administration resulted in a significant decrease in fasting plasma free fatty acids, fibrinogen, thrombin-antithrombin complex and reaction product of malondialdehyde with thiobarbituric acid (TBARS) levels, in absence of significant difference in fasting plasma insulin levels.	repaglinide	13-24	insulin	Homo sapiens	289-296
16142016-8	2005	At time 120" of meal test, repaglinide vs glimepiride administration was associated with a significant decline in plasma triglycerides, free fatty acids, fibrinogen, Plasminogen Activator Inhibitor-1, plasmin-alpha(2)-antiplasmin complex, thrombin-antithrombin complex, TBARS levels and increase in plasma HDL-cholesterol levels.	repaglinide	27-38	fibrinogen beta chain	Homo sapiens	154-164
16142016-8	2005	At time 120" of meal test, repaglinide vs glimepiride administration was associated with a significant decline in plasma triglycerides, free fatty acids, fibrinogen, Plasminogen Activator Inhibitor-1, plasmin-alpha(2)-antiplasmin complex, thrombin-antithrombin complex, TBARS levels and increase in plasma HDL-cholesterol levels.	repaglinide	27-38	serpin family E member 1	Homo sapiens	166-199
16142016-8	2005	At time 120" of meal test, repaglinide vs glimepiride administration was associated with a significant decline in plasma triglycerides, free fatty acids, fibrinogen, Plasminogen Activator Inhibitor-1, plasmin-alpha(2)-antiplasmin complex, thrombin-antithrombin complex, TBARS levels and increase in plasma HDL-cholesterol levels.	repaglinide	27-38	coagulation factor II, thrombin	Homo sapiens	239-247
16142016-8	2005	At time 120" of meal test, repaglinide vs glimepiride administration was associated with a significant decline in plasma triglycerides, free fatty acids, fibrinogen, Plasminogen Activator Inhibitor-1, plasmin-alpha(2)-antiplasmin complex, thrombin-antithrombin complex, TBARS levels and increase in plasma HDL-cholesterol levels.	repaglinide	27-38	serpin family C member 1	Homo sapiens	248-260
16142016-9	2005	In repaglinide group a negative correlation between insulin secretion during 1st phase of meal-test and plasma TBARS levels (r = -0.55; P < 0.03) at time 120" was found.	repaglinide	3-14	insulin	Homo sapiens	52-59
15938025-9	2005	In chronic renal failure, the oral agents that can be used therefore include the insulin secretagogues repaglinide and nateglinide and the thiazolidinediones (rosiglitazone and pioglitazone) with caution.	repaglinide	103-114	insulin	Homo sapiens	81-88
20496449-4	2005	Two other oral antidiabetic drugs that work by stimulating insulin secretion, repaglinide and nateglinide, are available in the U.S.	repaglinide	78-89	insulin	Homo sapiens	59-66
15855557-1	2005	OBJECTIVE: To assess the effects of incremental doses of repaglinide on postprandial insulin and glucose profiles after a standard 500-kcal test meal.	repaglinide	57-68	insulin	Homo sapiens	85-92
15855557-6	2005	Proinsulin-to-insulin ratios at 30 and 60 min improved with increasing doses of repaglinide; higher drug doses (2 and 4 mg) were more effective than the 0.5- and 1-mg doses.	repaglinide	80-91	insulin	Homo sapiens	0-10
15855557-6	2005	Proinsulin-to-insulin ratios at 30 and 60 min improved with increasing doses of repaglinide; higher drug doses (2 and 4 mg) were more effective than the 0.5- and 1-mg doses.	repaglinide	80-91	insulin	Homo sapiens	3-10
15846457-8	2005	The antidiabetic repaglinide and HMG CoA reductase inhibitor fluvastatin were found to inhibit hPEPT1 with sub-millimolar potency (IC(50) 178 +/- 1.0 and 337 +/- 4 microM, respectively).	repaglinide	17-28	solute carrier family 15 member 1	Homo sapiens	95-101
15678092-0	2005	Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.	repaglinide	31-42	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	0-6
15678092-15	2005	The results suggest that Kir6.2 causes a conformational change in SUR1 required for high-affinity repaglinide binding, or that the high-affinity repaglinide-binding site includes contributions from both SUR1 and Kir6.2.	repaglinide	98-109	ATP binding cassette subfamily C member 8	Homo sapiens	66-70
15678092-15	2005	The results suggest that Kir6.2 causes a conformational change in SUR1 required for high-affinity repaglinide binding, or that the high-affinity repaglinide-binding site includes contributions from both SUR1 and Kir6.2.	repaglinide	145-156	ATP binding cassette subfamily C member 8	Homo sapiens	203-207
15678092-4	2005	In this study, we investigate the interaction of the hypoglycaemic agents repaglinide and glibenclamide with SUR1 and the effect of Kir6.2 on this interaction.	repaglinide	74-85	ATP binding cassette subfamily C member 8	Homo sapiens	109-113
15678092-5	2005	We further explore how the binding properties of repaglinide and glibenclamide are affected by functional uncoupling of SUR1 and Kir6.2 in Kir6.2DeltaN14/SUR1 channels.	repaglinide	49-60	ATP binding cassette subfamily C member 8	Homo sapiens	120-124
15678092-5	2005	We further explore how the binding properties of repaglinide and glibenclamide are affected by functional uncoupling of SUR1 and Kir6.2 in Kir6.2DeltaN14/SUR1 channels.	repaglinide	49-60	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	129-135
15678092-5	2005	We further explore how the binding properties of repaglinide and glibenclamide are affected by functional uncoupling of SUR1 and Kir6.2 in Kir6.2DeltaN14/SUR1 channels.	repaglinide	49-60	ATP binding cassette subfamily C member 8	Homo sapiens	154-158
15678092-7	2005	Repaglinide was found to bind with low affinity (K(D)=59+/-16 nM) to SUR1 alone, but with high affinity (increased approximately 150-fold) when SUR1 was co-expressed with Kir6.2 (K(D)=0.42+/-0.03 nM).	repaglinide	0-11	ATP binding cassette subfamily C member 8	Homo sapiens	69-73
15678092-7	2005	Repaglinide was found to bind with low affinity (K(D)=59+/-16 nM) to SUR1 alone, but with high affinity (increased approximately 150-fold) when SUR1 was co-expressed with Kir6.2 (K(D)=0.42+/-0.03 nM).	repaglinide	0-11	ATP binding cassette subfamily C member 8	Homo sapiens	144-148
15678092-7	2005	Repaglinide was found to bind with low affinity (K(D)=59+/-16 nM) to SUR1 alone, but with high affinity (increased approximately 150-fold) when SUR1 was co-expressed with Kir6.2 (K(D)=0.42+/-0.03 nM).	repaglinide	0-11	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	171-177
15678092-10	2005	Repaglinide bound with low affinity (K(D)=51+/-23 nM) to SUR1 co-expressed with Kir6.2DeltaN14.	repaglinide	0-11	ATP binding cassette subfamily C member 8	Homo sapiens	57-61
15678092-13	2005	In whole-cell patch-clamp experiments inhibition of Kir6.2DeltaN14/SUR1 currents by both repaglinide and nateglinde is abolished.	repaglinide	89-100	ATP binding cassette subfamily C member 8	Homo sapiens	67-71
16372821-12	2005	Repaglinide is metabolised by CYP2C8 and, according to clinical studies, CYP2C8*3 carriers had higher clearance than carriers of the wild-type genotypes; however, this was not consistent with in vitro data and therefore further studies are needed.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
15729954-1	2005	BACKGROUND: Repaglinide, a new insulin secretagogue, is purported to be as effective as sulphonylurea but is less hypoglycemic-prone.	repaglinide	12-23	insulin	Homo sapiens	31-38
16372821-12	2005	Repaglinide is metabolised by CYP2C8 and, according to clinical studies, CYP2C8*3 carriers had higher clearance than carriers of the wild-type genotypes; however, this was not consistent with in vitro data and therefore further studies are needed.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	73-79
15294453-8	2004	Taurine at the concentration of 10 mM enhanced the high-affinity bindings of glibenclamide and repaglinide on all types of SUR, whereas the low-affinity binding on Kir6.2 was not affected.	repaglinide	95-106	ATP binding cassette subfamily C member 8	Rattus norvegicus	123-126
15601807-1	2005	Cytochrome P450 2C8 is involved in the metabolism of drugs such as paclitaxel, repaglinide, rosiglitazone, and cerivastatin, among others.	repaglinide	79-90	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-19
15386823-7	2004	While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 pmol L(-1) (P = 0.06) and C-peptide 0.81 +/- 0.19 vs 1.14 +/- 0.18 nmol L(-1) (P = 0.05) for repaglinide vs glibenclamide, respectively).	repaglinide	125-136	insulin	Homo sapiens	66-73
15386823-7	2004	While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 pmol L(-1) (P = 0.06) and C-peptide 0.81 +/- 0.19 vs 1.14 +/- 0.18 nmol L(-1) (P = 0.05) for repaglinide vs glibenclamide, respectively).	repaglinide	125-136	insulin	Homo sapiens	75-85
15386823-7	2004	While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 pmol L(-1) (P = 0.06) and C-peptide 0.81 +/- 0.19 vs 1.14 +/- 0.18 nmol L(-1) (P = 0.05) for repaglinide vs glibenclamide, respectively).	repaglinide	125-136	insulin	Homo sapiens	90-99
15386823-7	2004	While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 pmol L(-1) (P = 0.06) and C-peptide 0.81 +/- 0.19 vs 1.14 +/- 0.18 nmol L(-1) (P = 0.05) for repaglinide vs glibenclamide, respectively).	repaglinide	125-136	insulin	Homo sapiens	78-85
15386823-7	2004	While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 pmol L(-1) (P = 0.06) and C-peptide 0.81 +/- 0.19 vs 1.14 +/- 0.18 nmol L(-1) (P = 0.05) for repaglinide vs glibenclamide, respectively).	repaglinide	125-136	insulin	Homo sapiens	207-217
15386823-7	2004	While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 pmol L(-1) (P = 0.06) and C-peptide 0.81 +/- 0.19 vs 1.14 +/- 0.18 nmol L(-1) (P = 0.05) for repaglinide vs glibenclamide, respectively).	repaglinide	125-136	insulin	Homo sapiens	265-274
15386823-8	2004	CONCLUSIONS: Following glucose stimulation, plasma glucose levels, and insulin concentration decrease more rapidly after repaglinide treatment than after glibenclamide.	repaglinide	121-132	insulin	Homo sapiens	71-78
15197140-8	2004	CIMT regression, defined as a decrease of >0.020 mm, was observed in 52% of diabetics receiving repaglinide and in 18% of those receiving glyburide (P<0.01).	repaglinide	99-110	CIMT	Homo sapiens	0-4
15324515-4	2004	At the end of the study, changes in HbA1c from baseline were -1.28% points and -0.67% points for repaglinide/metformin and nateglinide/metformin, respectively.	repaglinide	97-108	hemoglobin subunit alpha 1	Homo sapiens	36-40
15197140-9	2004	Interleukin-6 (P=0.04) and C-reactive protein (P=0.02) decreased more in the repaglinide group than in the glyburide group.	repaglinide	77-88	interleukin 6	Homo sapiens	0-13
15197140-9	2004	Interleukin-6 (P=0.04) and C-reactive protein (P=0.02) decreased more in the repaglinide group than in the glyburide group.	repaglinide	77-88	C-reactive protein	Homo sapiens	27-45
12817528-6	2003	Concomitant treatment with CYP3A4 substrates altered mean AUC0-5 h and mean Cmax for repaglinide by 1% and 17% (ethinyloestradiol/levonorgestrel), 2% and 27% (simvastatin), or 11% and 3% (nifedipine).	repaglinide	85-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
15334790-1	2004	This study was designed to compare the effects of repaglinide plus acarbose combination treatment to repaglinide alone on postprandial glucose, serum insulin, C-peptide and proinsulin concentrations.	repaglinide	50-61	insulin	Homo sapiens	173-183
15099124-26	2004	Repaglinide, a meglitinide analogue, is an oral insulin secretagogue that reduces postprandial glucose excursions by targeting postprandial insulin release.	repaglinide	0-11	insulin	Homo sapiens	48-55
15099124-31	2004	In general, results showed statistically significant improvements in glycaemic control when repaglinide was used in combination with metformin, various thiazolidinediones, or metformin plus bedtime insulin compared with monotherapy with either comparator drug in each study (or metformin plus bedtime insulin in one trial).	repaglinide	92-103	insulin	Homo sapiens	301-308
15099124-40	2004	Repaglinide is metabolised by the cytochrome P450 (CYP) 3A4 enzyme system and therefore has the potential to interact with other CYP3A4 substrates when administered concurrently.	repaglinide	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
14632720-10	2003	Both treatments were associated with significant improvements in Diabetes Treatment Satisfaction [Diabetes Treatment Satisfaction Questionnaire-potential range 0 (min) to 36 (max)]; in the insulin/gliclazide group, by 4.9 +/- 1.1 points to 33.3 +/- 0.6 (P<0.0001) and by 3.0 +/- 0.9 points to 34.6 +/- 0.4 (P=0.0006) in the insulin/repaglinide group (P=0.29 between groups).	repaglinide	335-346	insulin	Homo sapiens	189-196
14614647-9	2003	Nateglinide and repaglinide as short-acting insulin secretagogues may be associated with a reduced risk of hypoglycaemia compared with glibenclamide, in particular when dosed flexibly.	repaglinide	16-27	insulin	Homo sapiens	44-51
12919179-0	2003	CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.	repaglinide	121-132	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
12919179-0	2003	CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.	repaglinide	121-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
12919179-0	2003	CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.	repaglinide	121-132	insulin	Homo sapiens	100-107
12919179-1	2003	AIMS: To identify the principal human cytochrome P450 (CYP) enzyme(s) responsible for the human in vitro biotransformation of repaglinide.	repaglinide	126-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
12919179-1	2003	AIMS: To identify the principal human cytochrome P450 (CYP) enzyme(s) responsible for the human in vitro biotransformation of repaglinide.	repaglinide	126-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
12919179-2	2003	Previous experiments have identified CYP3A4 as being mainly responsible for the in vitro metabolism of repaglinide, but the results of clinical investigations have suggested that more than one enzyme may be involved in repaglinide biotransformation.	repaglinide	103-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
12919179-3	2003	METHODS: [14C]-Repaglinide was incubated with recombinant CYP and with human liver microsomes (HLM) from individual donors in the presence of inhibitory antibodies specific for individual CYP enzymes.	repaglinide	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-61
12919179-3	2003	METHODS: [14C]-Repaglinide was incubated with recombinant CYP and with human liver microsomes (HLM) from individual donors in the presence of inhibitory antibodies specific for individual CYP enzymes.	repaglinide	15-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
12919179-5	2003	RESULTS: CYP3A4 and CYP2C8 were found to be responsible for the conversion of repaglinide into its two primary metabolites, M4 (resulting from hydroxylation on the piperidine ring system) and M1 (an aromatic amine).	repaglinide	78-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-15
12919179-5	2003	RESULTS: CYP3A4 and CYP2C8 were found to be responsible for the conversion of repaglinide into its two primary metabolites, M4 (resulting from hydroxylation on the piperidine ring system) and M1 (an aromatic amine).	repaglinide	78-89	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
12919179-17	2003	CONCLUSIONS: The results confirm an important role for both CYP3A4 and CYP2C8 in the human in vitro biotransformation of repaglinide.	repaglinide	121-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
12919179-17	2003	CONCLUSIONS: The results confirm an important role for both CYP3A4 and CYP2C8 in the human in vitro biotransformation of repaglinide.	repaglinide	121-132	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	71-77
12919179-18	2003	This dual CYP biotransformation may have consequences for the clinical pharmacokinetics and drug-drug interactions involving repaglinide if one CYP pathway has sufficient capacity to compensate if the other is inhibited.	repaglinide	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-13
12919179-18	2003	This dual CYP biotransformation may have consequences for the clinical pharmacokinetics and drug-drug interactions involving repaglinide if one CYP pathway has sufficient capacity to compensate if the other is inhibited.	repaglinide	125-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-147
12817528-0	2003	Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.	repaglinide	131-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
12817528-1	2003	The object of this study was to analyze drug interactions between repaglinide, a short-acting insulin secretagogue, and five other drugs interacting with CYP3A4: ketoconazole, rifampicin, ethinyloestradiol/levonorgestrel (in an oral contraceptive), simvastatin, and nifedipine.	repaglinide	66-77	insulin	Homo sapiens	94-101
12817528-1	2003	The object of this study was to analyze drug interactions between repaglinide, a short-acting insulin secretagogue, and five other drugs interacting with CYP3A4: ketoconazole, rifampicin, ethinyloestradiol/levonorgestrel (in an oral contraceptive), simvastatin, and nifedipine.	repaglinide	66-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-160
15239026-7	2004	The insulin sensitivity index (ISI) was increased by 35 % after 1 week of combination therapy with repaglinide plus metformin (1.11 +/- 0.03 x 10 (2) vs. 0.83 +/- 0.21 x 10 (2) mg x kg (-1) body weight x min (-1) x pmol (-1) x l, respectively; p = 0.033).	repaglinide	99-110	insulin	Homo sapiens	4-11
15239026-8	2004	Repaglinide increased early and late phases of insulin responses in HC, without markedly enhancing insulin secretion in euglycaemia.	repaglinide	0-11	insulin	Homo sapiens	47-54
15239026-9	2004	Repaglinide in combination with metformin produced a significant enhancement of ISI, suggesting a synergistic effect on insulin sensitivity.	repaglinide	0-11	insulin	Homo sapiens	120-127
15025742-0	2004	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.	repaglinide	73-84	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	4-10
15025742-1	2004	AIMS: Our aim was to investigate the effect of the CYP2C8 inhibitor trimethoprim on the pharmacokinetics and pharmacodynamics of the antidiabetic drug repaglinide, and to examine the influence of the former on the metabolism of the latter in vitro.	repaglinide	151-162	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	51-57
15025742-10	2004	CONCLUSIONS: Trimethoprim raised the plasma concentrations of repaglinide probably by inhibiting its CYP2C8-mediated biotransformation.	repaglinide	62-73	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	101-107
14715864-0	2004	The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.	repaglinide	44-55	insulin	Homo sapiens	4-11
14715864-2	2004	The present study was undertaken to explore in more detail a possible influence of a single dose of SU (glibenclamide) and a non-SU (repaglinide) insulin secretagogue on circulating GH dynamics.	repaglinide	133-144	insulin	Homo sapiens	146-153
14534525-0	2003	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.	repaglinide	75-86	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	16-22
14534525-1	2003	OBJECTIVE: Our objective was to investigate the effects of genetic polymorphisms of cytochrome P450 (CYP) 2C8 on the pharmacokinetics and pharmacodynamics of the meglitinide analog antidiabetic drug repaglinide.	repaglinide	199-210	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	84-109
14534525-2	2003	METHODS: We genotyped 28 healthy volunteers who had participated in our pharmacokinetic studies on repaglinide for variant alleles of the CYP2C8 gene.	repaglinide	99-110	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	138-144
14534525-9	2003	The mean AUC(0- infinity ) of repaglinide was 45% (P <.005) lower and the peak concentration in plasma was 39% lower (P <.05) in subjects with the CYP2C8*1/*3 genotype compared with those with the CYP2C8*1/*1 genotype.	repaglinide	30-41	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	153-159
14534525-11	2003	CONCLUSIONS: Unexpectedly, the CYP2C8*3 variant allele was associated with reduced plasma concentrations of repaglinide.	repaglinide	108-119	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	31-37
12817528-13	2003	These results are probably explained by the metabolic pathway of repaglinide that involves other enzymes than CYP3A4, reflected to some extent by a small change in repaglinide pharmacodynamics.	repaglinide	65-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
12817528-14	2003	Thus, careful monitoring of blood glucose in repaglinide-treated patients receiving strong inhibitors or inducers of CYP3A4 is recommended, and an increase in repaglinide dose may be necessary.	repaglinide	45-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
12702002-9	2002	Repaglinide, a novel prandial glucose regulator, improves the insulin secretory burst mass in healthy people.	repaglinide	0-11	insulin	Homo sapiens	62-69
12749508-14	2003	Repaglinide significantly lowered levels of Lp(a), PAI-1, and Hcy after 12 months (all, P < 0.05 vs baseline).	repaglinide	0-11	lipoprotein(a)	Homo sapiens	44-49
12749508-14	2003	Repaglinide significantly lowered levels of Lp(a), PAI-1, and Hcy after 12 months (all, P < 0.05 vs baseline).	repaglinide	0-11	serpin family E member 1	Homo sapiens	51-56
12482641-10	2003	There was a significant increase after repaglinide in total serum antioxidant capacity (P<0.05) and serum SOD activity (P<0.0004); the difference compared to the control group being significant (P<0.002).	repaglinide	39-50	superoxide dismutase 1	Homo sapiens	109-112
12652355-4	2003	RESULTS: Although oral administration of nateglinide and repaglinide elicited similar maximum increments of plasma insulin (+403 and +448 pmol/l, respectively), the effects of nateglinide were more rapidly manifest and less prolonged.	repaglinide	57-68	insulin	Macaca fascicularis	115-122
12652355-8	2003	Repaglinide increased total insulin release (AUC(0-210)=298 nmol/l min) and reduced glucose excursions by 53%.	repaglinide	0-11	insulin	Macaca fascicularis	28-35
12702004-7	2002	The novel insulin secretagogue repaglinide, by contrast, augments early-phase prandial insulin secretion when taken before meals, as shown by studies in non-diabetic people and patients with newly diagnosed, previously untreated T2DM.	repaglinide	31-42	insulin	Homo sapiens	10-17
12702004-7	2002	The novel insulin secretagogue repaglinide, by contrast, augments early-phase prandial insulin secretion when taken before meals, as shown by studies in non-diabetic people and patients with newly diagnosed, previously untreated T2DM.	repaglinide	31-42	insulin	Homo sapiens	87-94
12702004-0	2002	Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.	repaglinide	119-130	insulin	Homo sapiens	21-28
12196472-1	2002	Repaglinide and nateglinide represent a new class of insulin secretagogues, structurally unrelated to sulphonylureas, that were developed for the treatment of type 2 diabetes.	repaglinide	0-11	insulin	Homo sapiens	53-60
12702004-8	2002	Repaglinide exerts its greatest effect on the insulin secretion rate during the first 30 min after a meal is started, thereby going some way to restoring the early insulin secretion curve seen after a meal in non-diabetic people.	repaglinide	0-11	insulin	Homo sapiens	46-53
12702004-8	2002	Repaglinide exerts its greatest effect on the insulin secretion rate during the first 30 min after a meal is started, thereby going some way to restoring the early insulin secretion curve seen after a meal in non-diabetic people.	repaglinide	0-11	insulin	Homo sapiens	164-171
12351462-9	2002	The Diabetes Treatment Satisfaction Questionnaire score (potential range 0 [minimum] to 36 [maximum]) increased from 32.4 +/- 0.8 to 34.1 +/- 0.5 (P = 0.01) with insulin/metformin but decreased from 32.5 +/- 0.9 to 29.1 +/- 1.3 (P < 0.002) with insulin/repaglinide.	repaglinide	256-267	insulin	Homo sapiens	162-169
12196472-3	2002	Nateglinide and repaglinide dose-dependently inhibited whole-cell Kir6.2/SUR1 currents with half-maximal inhibitory concentration (IC(50)) values of 800 and 21 nmol/l, respectively.	repaglinide	16-27	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	66-72
12196472-3	2002	Nateglinide and repaglinide dose-dependently inhibited whole-cell Kir6.2/SUR1 currents with half-maximal inhibitory concentration (IC(50)) values of 800 and 21 nmol/l, respectively.	repaglinide	16-27	ATP binding cassette subfamily C member 8	Homo sapiens	73-77
11194214-5	2001	RESULTS: Treatment with repaglinide significantly improved glycemic control with respect to baseline and placebo, reducing HbA1c by 1.14% from baseline and fasting plasma glucose by 1.8 mmol/l.	repaglinide	24-35	hemoglobin subunit alpha 1	Homo sapiens	123-127
12073790-6	2002	A more physiological post-meal profile of insulin may be obtained in type 2 diabetes by using new insulin secretagogues of the glinide family (repaglinide, nateglinide) with an earlier and shorter insulinotropic action or, mainly in type 1 diabetes but also in type 2 diabetes, by using short-acting insulin analogues (lispro.	repaglinide	143-154	insulin	Homo sapiens	42-49
12073790-6	2002	A more physiological post-meal profile of insulin may be obtained in type 2 diabetes by using new insulin secretagogues of the glinide family (repaglinide, nateglinide) with an earlier and shorter insulinotropic action or, mainly in type 1 diabetes but also in type 2 diabetes, by using short-acting insulin analogues (lispro.	repaglinide	143-154	insulin	Homo sapiens	98-105
12073790-6	2002	A more physiological post-meal profile of insulin may be obtained in type 2 diabetes by using new insulin secretagogues of the glinide family (repaglinide, nateglinide) with an earlier and shorter insulinotropic action or, mainly in type 1 diabetes but also in type 2 diabetes, by using short-acting insulin analogues (lispro.	repaglinide	143-154	insulin	Homo sapiens	98-105
11815507-7	2002	RESULTS: Repaglinide increased postprandial insulin levels and markedly reduced postprandial glucose levels relative to baseline in both groups.	repaglinide	9-20	insulin	Homo sapiens	44-51
11574430-0	2001	Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.	repaglinide	66-77	insulin	Homo sapiens	0-7
11574430-1	2001	OBJECTIVE: Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia.	repaglinide	79-90	insulin	Homo sapiens	11-18
11483229-10	2001	Test meal assessments confirmed that repaglinide effectively controls glucose levels by stimulating mealtime insulin secretion.	repaglinide	37-48	insulin	Homo sapiens	109-116
11483229-12	2001	Twice-daily meal-related insulin secretagogue therapy with repaglinide, a new short and rapid-acting prandial glucose regulator, is capable of improving all measures of glycaemic control without increased hypoglycaemia or fasting hyperinsulinaemia.	repaglinide	59-70	insulin	Homo sapiens	25-32
11440368-1	2001	AIMS/HYPOTHESIS: The carbamoylbenzoic acid derivative repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell.	repaglinide	54-65	insulin S homeolog	Xenopus laevis	91-98
12432213-0	2002	Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.	repaglinide	0-11	insulin	Homo sapiens	28-35
12189909-9	2002	Prandial oral antidiabetic agents such as alpha-glucosidase inhibitors (acarbose, miglitol) and rapidly acting insulin secretagogues (nateglinide, repaglinide) have recently been introduced to improve the control of post-prandial hyperglycemia.	repaglinide	147-158	insulin	Homo sapiens	111-118
12405866-16	2002	Although there are no formal studies available, calcium channel antagonists and repaglinide may have significant interactions and toxicity when used with HIV protease inhibitors because of their metabolism by CYP3A4.	repaglinide	80-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	209-215
11525087-4	2001	Repaglinide is an insulin secretion enhancer with a different mechanism of action to the sulphonylureas, which means it does not continuously stimulate insulin secretion.	repaglinide	0-11	insulin	Homo sapiens	18-25
11440368-8	2001	MgADP potentiated the inhibitory effect of repaglinide on Kir6.2/SUR1 and (to a lesser extent) Kir6.2/SUR2B, but not on Kir6.2/SUR2A.	repaglinide	43-54	ATP-binding cassette sub-family C member 8	Xenopus laevis	65-69
11472451-8	2001	Change in HbA1c from baseline was significantly better with repaglinide than with glipizide after 12 months (P < 0.05).	repaglinide	60-71	hemoglobin subunit alpha 1	Homo sapiens	10-14
11194245-8	2001	After 2 mg repaglinide, peak insulin concentrations were delayed and returned to baseline more slowly than with nateglinide treatment.	repaglinide	11-22	insulin	Homo sapiens	29-36
11577798-2	2001	Like the sulphonylureas, repaglinide reduces blood glucose by stimulating insulin release from pancreatic beta-cells, but differs from these and other antidiabetic agents in its structure, binding profile, duration of action and mode of excretion.	repaglinide	25-36	insulin	Homo sapiens	74-81
11577798-7	2001	Repaglinide showed additive effects when used in combination with other oral antidiabetic agents including metformin, troglitazone, rosiglitazone and pioglitazone, and intermediate-acting insulin (NPH) given at bedtime.	repaglinide	0-11	insulin	Homo sapiens	188-195
10929931-7	2000	The second modality involves increasing insulin availability by the administration of exogenous insulin, insulin analogues, sulphonylureas and the new insulin secretagogue, repaglinide.	repaglinide	173-184	insulin	Homo sapiens	40-47
11460577-4	2001	There are also newer insulin secretagogues (such as neteglinide and repaglinide) with a rapid onset of action on the beta-cell, therefore inducing a more physiological profile of insulin secretion during meals.	repaglinide	68-79	insulin	Homo sapiens	21-28
11190420-7	2000	Repaglinide and nateglinide are absorbed rapidly, stimulate insulin release within a few minutes, are rapidly metabolised in the liver and are mainly excreted in the bile.	repaglinide	0-11	insulin	Homo sapiens	60-67
11063282-7	2000	More recently, the availability of the rapid or early augmentor of insulin secretion--repaglinide--provides a means for restoring prandial glucose regulation with oral therapy.	repaglinide	86-97	insulin	Homo sapiens	67-74
11063282-9	2000	Prandial glucose regulation with repaglinide has also been demonstrated to provide synergies when used as combination therapy with insulin sensitising agents.	repaglinide	33-44	insulin	Homo sapiens	131-138
10959157-2	2000	Repaglinide is the first stimulator of insulin secretion from the new meglitinide family.	repaglinide	0-11	insulin	Homo sapiens	39-46
10959157-4	2000	In preclinical studies, the insulin-stimulating effect of repaglinide has been found to be 10 to 20 times more potent than that of glibenclamide.	repaglinide	58-69	insulin	Homo sapiens	28-35
11249478-1	2000	Repaglinide is a novel insulin secretagogue that was developed as a prandial glucose regulator for the treatment of people with Type 2 diabetes mellitus.	repaglinide	0-11	insulin	Homo sapiens	23-30
11249478-6	2000	Importantly, the pharmacokinetic properties of repaglinide, are expected to reduce the risk of hypoglycaemia in comparison to the conventional insulin secretagogues (sulphonylureas).	repaglinide	47-58	insulin	Homo sapiens	143-150
10857945-10	2000	CONCLUSIONS: A single dose of repaglinide (0.5-4.0 mg) before breakfast improves insulin secretion and reduces prandial hyperglycemia dose-dependently Administration of repaglinide had no effect on insulin secretion with the second meal, which was consumed 4 h after breakfast.	repaglinide	30-41	insulin	Homo sapiens	81-88
10857945-0	2000	Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.	repaglinide	95-106	insulin	Homo sapiens	19-26
10872292-6	2000	Among the stimulators of insulin secretion are the sulfonylureas (e.g. glibenclamide, glibonuride, glisoxepid, glimepiride), and the so-called prandial glucose regulators, such as repaglinide, which differ from the sulfonylureas both chemically and in their pharmacodynamic properties.	repaglinide	180-191	insulin	Homo sapiens	25-32
10834429-2	2000	The aim of this study was to explore actions of repaglinide on the rapid pulsatile insulin release by high-frequency insulin sampling and analysis of insulin-concentration time series.	repaglinide	48-59	insulin	Homo sapiens	83-90
10834429-2	2000	The aim of this study was to explore actions of repaglinide on the rapid pulsatile insulin release by high-frequency insulin sampling and analysis of insulin-concentration time series.	repaglinide	48-59	insulin	Homo sapiens	117-124
10834429-2	2000	The aim of this study was to explore actions of repaglinide on the rapid pulsatile insulin release by high-frequency insulin sampling and analysis of insulin-concentration time series.	repaglinide	48-59	insulin	Homo sapiens	117-124
10834429-7	2000	RESULTS: Average insulin concentration was increased after repaglinide administration (basal vs. stimulated period, P values are placebo vs. repaglinide) (25.1 +/- 3.6 vs. 33.5 +/- 4.1 pmol/l, P < 0.001).	repaglinide	59-70	insulin	Homo sapiens	17-24
10834429-7	2000	RESULTS: Average insulin concentration was increased after repaglinide administration (basal vs. stimulated period, P values are placebo vs. repaglinide) (25.1 +/- 3.6 vs. 33.5 +/- 4.1 pmol/l, P < 0.001).	repaglinide	141-152	insulin	Homo sapiens	17-24
10834429-8	2000	Insulin secretory burst mass (15.8 +/- 2.2 vs. 19.6 +/- 2.8 pmol x l(-1) x pulse(-1), P = 0.02) and amplitude (6.1 +/- 0.9 vs. 7.7 +/- 1.2 pmol x l(-1) x min(-1), P = 0.008) were augmented after repaglinide administration.	repaglinide	195-206	insulin	Homo sapiens	0-7
10834429-10	2000	ApEn increased significantly after repaglinide administration (0.623 +/- 0.045 vs. 0.670 +/- 0.034, P = 0.04), suggesting less orderly oscillatory patterns of insulin release.	repaglinide	35-46	insulin	Homo sapiens	159-166
10834429-11	2000	CONCLUSIONS: In conclusion, a single dose of repaglinide amplifies insulin secretory burst mass (and basal secretion) with no change in burst frequency.	repaglinide	45-56	insulin	Homo sapiens	67-74
10857945-5	2000	RESULTS: During the first meal period (0-240 min), administration of repaglinide reduced significantly the area under the curve (AUC) for glucose concentration and significantly increased the AUC for insulin levels, C-peptide levels, and the insulin secretion rate.	repaglinide	69-80	insulin	Homo sapiens	200-207
10857945-5	2000	RESULTS: During the first meal period (0-240 min), administration of repaglinide reduced significantly the area under the curve (AUC) for glucose concentration and significantly increased the AUC for insulin levels, C-peptide levels, and the insulin secretion rate.	repaglinide	69-80	insulin	Homo sapiens	242-249
10857945-7	2000	The effect of repaglinide administration on insulin secretion was most pronounced in the early prandial period.	repaglinide	14-25	insulin	Homo sapiens	44-51
10664920-1	2000	Repaglinide is a novel insulin secretagogue developed in response to the need for a fast-acting, oral prandial glucose regulator for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.	repaglinide	0-11	insulin	Homo sapiens	23-30
11060717-1	2000	Repaglinide (NovoNorm((R))) is a novel oral antidiabetic agent, the first of a new class of insulin secretagogues known as the prandial glucose regulators to be approved for use in patients with Type 2 diabetes.	repaglinide	0-11	insulin	Homo sapiens	92-99
11060717-3	2000	After repaglinide administration, the resulting insulin profile reflects that of healthy individuals more closely, providing tighter glycaemic control and reducing the risk of hypoglycaemic events.	repaglinide	6-17	insulin	Homo sapiens	48-55
11225759-11	2000	When glucose targets are not met using repaglinide monotherapy, the combination of repaglinide with metformin can further improve glycaemic control by enhancing insulin secretion and improving insulin sensitivity.	repaglinide	83-94	insulin	Homo sapiens	161-168
10664920-1	2000	Repaglinide is a novel insulin secretagogue developed in response to the need for a fast-acting, oral prandial glucose regulator for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.	repaglinide	0-11	insulin	Homo sapiens	162-169
10631622-3	2000	For the repaglinide treatment groups at the end of the study, changes in HbA1c from baseline values ranged from 1.8 to 1.9 percentage points lower than the placebo group.	repaglinide	8-19	hemoglobin subunit alpha 1	Homo sapiens	73-77
11475269-4	1999	Efficacy of repaglinide therapy was assessed by measuring changes from baseline in mean levels of blood glucose (BGmean), fasting serum glucose (FSG), and mean levels of serum insulin (INSmean).	repaglinide	12-23	insulin	Homo sapiens	176-183
10605995-4	1999	Two new long-acting sulfonylureas (glimepiride and extended-release glipizide) and a short-acting sulfonylurea-like agent (repaglinide) simply and reliably augment the patient"s insulin supply.	repaglinide	123-134	insulin	Homo sapiens	178-185
10746004-3	1999	During type 2 diabetes mellitus, repaglinide is the first fast-acting oral antidiabetic drug able to stimulate endogenous insulin secretion during meal by mimicking physiological insulin secretion pattern.	repaglinide	33-44	insulin	Homo sapiens	122-129
10746004-3	1999	During type 2 diabetes mellitus, repaglinide is the first fast-acting oral antidiabetic drug able to stimulate endogenous insulin secretion during meal by mimicking physiological insulin secretion pattern.	repaglinide	33-44	insulin	Homo sapiens	179-186
10498841-6	1999	However, repaglinide only weakly inhibited CFTR Cl- currents.	repaglinide	9-20	CF transmembrane conductance regulator	Homo sapiens	43-47
10522838-1	1999	The action of repaglinide, a carbamoylmethyl benzoic acid derivative, mimics the physiological insulin secretion that is deficient in Type 2 diabetes mellitus.	repaglinide	14-25	insulin	Homo sapiens	95-102
10820647-7	1999	Other recently introduced drugs include glimepiride and the meglitinide insulin secretagogue, repaglinide.	repaglinide	94-105	insulin	Homo sapiens	72-79
11220287-8	1999	Repaglinide, a new, fast-acting insulin secretagogue with a short duration of action, reduces postprandial hyperglycaemia when taken shortly before meals.	repaglinide	0-11	insulin	Homo sapiens	32-39
10501822-17	1999	These properties make repaglinide a suitable insulin secretagogue for all patients with type-2 diabetes who retain sufficient beta-cell function.	repaglinide	22-33	insulin	Homo sapiens	45-52
10333912-7	1999	Subjects receiving repaglinide either alone or in combination with metformin, had an increase in fasting levels of insulin between baseline and the end of the trial of 4.04 +/- 1.56 and 4.23 +/- 1.50 mU/l, respectively (P < 0.02).	repaglinide	19-30	insulin	Homo sapiens	115-122
10522838-2	1999	Repaglinide stimulates insulin release from beta-cells only in the presence of glucose.	repaglinide	0-11	insulin	Homo sapiens	23-30
10522838-4	1999	In one study, repaglinide (0.25-4.0 mg preprandially) caused a dose-dependent decrease in blood glucose and a non-dose-dependent increase in insulin over 4 weeks (all doses p < 0.001 vs. placebo).	repaglinide	14-25	insulin	Homo sapiens	141-148
9855316-1	1998	Repaglinide is a new, short-acting, insulin-releasing agent recently approved for the monotherapy of type 2 diabetes mellitus, and in combination with metformin in patients failing repaglinide or metformin monotherapy.	repaglinide	0-11	insulin	Homo sapiens	36-43
9802740-9	1998	Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P < 0.05).	repaglinide	188-199	insulin	Homo sapiens	43-50
9855316-2	1998	Repaglinide appears to trigger insulin release by regulating adenosine triphosphate-sensitive potassium channels on the surface of pancreatic beta cells, which in turn affect calcium influx, the principal mediator of insulin release.	repaglinide	0-11	insulin	Homo sapiens	31-38
9855316-2	1998	Repaglinide appears to trigger insulin release by regulating adenosine triphosphate-sensitive potassium channels on the surface of pancreatic beta cells, which in turn affect calcium influx, the principal mediator of insulin release.	repaglinide	0-11	insulin	Homo sapiens	217-224
15989662-4	1997	Four novel non-sulfonylurea insulin secretagogues are in advanced clinical development: A-4166, KAD-1229, BTS 67 582 and repaglinide.	repaglinide	121-132	insulin	Homo sapiens	28-35
9657067-3	1997	Both repaglinide (0.01 microM) and A-4166 (1.0 microM) stimulated insulin and somatostatin release, but failed to affect glucagon output, from pancreases exposed to 5.6 mM D-glucose.	repaglinide	5-16	insulin	Homo sapiens	66-73
9657067-5	1997	Although repaglinide was tested at a concentration a hundred times lower than that of A-4166, the drug-induced increase in both insulin and somatostatin secretion persisted for a longer time after exposure to repaglinide, than to A-4166.	repaglinide	209-220	insulin	Homo sapiens	128-135
9739505-1	1998	Repaglinide is a novel insulin secretagogue being developed for the management of type 2 (non-insulin-dependent) diabetes mellitus.	repaglinide	0-11	insulin	Homo sapiens	23-30
9868989-10	1998	In other studies, repaglinide caused a decrease of 5.8 mmol x l(-1) in peak postprandial glucose levels, and a decrease of 3.1 mmol x l(-1) in fasting levels with a reduction in HbA1c of 1.8% compared with placebo.	repaglinide	18-29	hemoglobin subunit alpha 1	Homo sapiens	178-182
8223830-6	1993	Fasting plasma insulin in the repaglinide group decreased from 80 (median value) to 67 pmol.l-1; it did not change in the glibenclamide group.	repaglinide	30-41	insulin	Homo sapiens	15-22
8944206-6	1996	A new class of drugs with insulin secretory capacity, of which repaglinide (NovoNorm) is the leading compound, is now in phase III clinical trials.	repaglinide	63-74	insulin	Homo sapiens	26-33
32475902-7	2021	At the end of monotherapy, insulin secretion relative to glucose elevation (ISG0-30: area under the curve of insulin from 0 to 30 min during MTT [AUC0-30 of IRI]/AUC0-30 of plasma glucose) was significantly increased only in the repaglinide group; ISG0-30 did not significantly increase in either group after the addition of alogliptin.ConclusionsThe addition of alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia.	repaglinide	229-240	insulin	Homo sapiens	27-34
34939558-1	2021	Repaglinide is an antidiabetic drug that works by stimulating insulin secretion from pancreatic beta cells.	repaglinide	0-11	insulin	Homo sapiens	62-69
33933705-0	2021	High-Performance affinity chromatographic studies of repaglinide and nateglinide interactions with normal and glyoxal- or methylglyoxal-modified human albumin serum.	repaglinide	53-64	albumin	Homo sapiens	151-158
34157903-7	2022	Remarkably, inhibiting FOXO3 with repaglinide delayed OTM by severely impairing mechanical force-induced bone formation in vivo.	repaglinide	34-45	forkhead box O3	Homo sapiens	23-28
32970826-8	2021	Recent studies have shown clinically significant increases in exposure to CYP2C8 substrates (repaglinide, dasabuvir, desloratidine) and a CYP2B6 substrate (s-sibutramine) following co-administration with clopidogrel, indicating that therapeutic strategies with clopidogrel should avoid these drugs.	repaglinide	93-104	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
33455494-4	2021	Eliminations from plasma of cilomilast, phenytoin, repaglinide, tolbutamide, and S-warfarin in the CYP2C19 PM group were significantly slow; these drugs are known substrates of human CYP2C8/9/19.	repaglinide	51-62	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	99-106
32475902-7	2021	At the end of monotherapy, insulin secretion relative to glucose elevation (ISG0-30: area under the curve of insulin from 0 to 30 min during MTT [AUC0-30 of IRI]/AUC0-30 of plasma glucose) was significantly increased only in the repaglinide group; ISG0-30 did not significantly increase in either group after the addition of alogliptin.ConclusionsThe addition of alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia.	repaglinide	229-240	insulin	Homo sapiens	109-116
32475902-7	2021	At the end of monotherapy, insulin secretion relative to glucose elevation (ISG0-30: area under the curve of insulin from 0 to 30 min during MTT [AUC0-30 of IRI]/AUC0-30 of plasma glucose) was significantly increased only in the repaglinide group; ISG0-30 did not significantly increase in either group after the addition of alogliptin.ConclusionsThe addition of alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia.	repaglinide	377-388	insulin	Homo sapiens	27-34
32475902-7	2021	At the end of monotherapy, insulin secretion relative to glucose elevation (ISG0-30: area under the curve of insulin from 0 to 30 min during MTT [AUC0-30 of IRI]/AUC0-30 of plasma glucose) was significantly increased only in the repaglinide group; ISG0-30 did not significantly increase in either group after the addition of alogliptin.ConclusionsThe addition of alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia.	repaglinide	377-388	insulin	Homo sapiens	109-116
33191904-5	2021	MATERIALS AND METHODS: An in silico DDI study was conducted using a population-based physiological pharmacokinetic simulator to estimate the CR of cytochrome P450 (CYP)3A4 for zolpidem, sildenafil, omeprazole, triazolam, and repaglinide.	repaglinide	225-236	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-171
33088647-1	2020	Repaglinide, an oral hypoglycemic agent, is a short-acting insulin secretagogue.	repaglinide	0-11	insulin	Homo sapiens	59-66
32401667-2	2020	In the present study, we examined eight compounds (bosentan, cerivastatin, fluvastatin, pitavastatin, pravastatin, repaglinide, rosuvastatin, valsartan) as typical organic anion transporting polypeptide (OATP) substrates and six compounds metabolized by P450 and non-P450 enzymes to evaluate the predictability of CLt, Vdss and plasma concentration-time profiles after intravenous administration to chimeric mice.The predicted CLt and Vdss of drugs that undergo OATP-mediated uptake and P450/non-P450-mediated metabolism reflected the observed data from humans within a three-fold error range.We also examined the possibility of predicting plasma concentration-time profiles of drugs that undergo OATP-mediated uptake using the complex Dedrick plot in chimeric mice.	repaglinide	115-126	solute carrier organic anion transporter family, member 1a6	Mus musculus	164-202
33210826-6	2021	Interestingly, repaglinide, one of the six antidiabetic drugs employed the highest docking score for Mpro , was similar to a previously predicted active molecule-nelfinavir, which is a potential anti-HIV and anti-COVID-19 drug.	repaglinide	15-26	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	101-105
33210826-7	2021	Moreover, we found repaglinide shared similar docking pose and pharmacophores with reported ligand (N3 inhibitor) and nelfinavir, demonstrating that repaglinide would interact with Mpro in a similar way.	repaglinide	19-30	n3	None	100-102
33210826-7	2021	Moreover, we found repaglinide shared similar docking pose and pharmacophores with reported ligand (N3 inhibitor) and nelfinavir, demonstrating that repaglinide would interact with Mpro in a similar way.	repaglinide	19-30	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	181-185
33210826-7	2021	Moreover, we found repaglinide shared similar docking pose and pharmacophores with reported ligand (N3 inhibitor) and nelfinavir, demonstrating that repaglinide would interact with Mpro in a similar way.	repaglinide	149-160	n3	None	100-102
33210826-7	2021	Moreover, we found repaglinide shared similar docking pose and pharmacophores with reported ligand (N3 inhibitor) and nelfinavir, demonstrating that repaglinide would interact with Mpro in a similar way.	repaglinide	149-160	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	181-185
33716254-2	2021	Repaglinide is an insulin secretagogue with a low hypoglycemic risk because of its rapid- and short-acting effects.	repaglinide	0-11	insulin	Homo sapiens	18-25
32621047-8	2020	HbA1C and basal insulin requirement were significantly lower in repaglinide group (p = 0.004, p = 0.0002).	repaglinide	64-75	insulin	Homo sapiens	16-23
32187961-0	2020	Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp.	repaglinide	87-98	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	111-115
32187961-1	2020	This study was devised to investigate if P-glycoprotein (P-gp) mediated the drug-drug interaction (DDI) between genistein and repaglinide.	repaglinide	126-137	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-55
32187961-1	2020	This study was devised to investigate if P-glycoprotein (P-gp) mediated the drug-drug interaction (DDI) between genistein and repaglinide.	repaglinide	126-137	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	57-61
32187961-10	2020	In conclusion, genistein inhibited the efflux of repaglinide mediated by P-gp in rats and in vitro.	repaglinide	49-60	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	73-77
32187961-11	2020	The findings suggested that the DDI between genistein and repaglinide is mediated by P-gp, and a dosage adjustment may be needed when they are co-administered in a clinical setting.	repaglinide	58-69	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	85-89
33088647-6	2020	Detection of plasma repaglinide 10 h after administration in this case indicates delayed elimination of the agent, which might be derived from reduced hepatocyte uptake due to inhibitory effects of nilotinib on OATP1B1 and reduced oxidation of the agents by inhibitory effects of nilotinib, mainly on CYP3A4 activities, and of febuxostat on CYP2C8 activities.	repaglinide	20-31	solute carrier organic anion transporter family member 1B1	Homo sapiens	211-218
33088647-6	2020	Detection of plasma repaglinide 10 h after administration in this case indicates delayed elimination of the agent, which might be derived from reduced hepatocyte uptake due to inhibitory effects of nilotinib on OATP1B1 and reduced oxidation of the agents by inhibitory effects of nilotinib, mainly on CYP3A4 activities, and of febuxostat on CYP2C8 activities.	repaglinide	20-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	301-307
33088647-6	2020	Detection of plasma repaglinide 10 h after administration in this case indicates delayed elimination of the agent, which might be derived from reduced hepatocyte uptake due to inhibitory effects of nilotinib on OATP1B1 and reduced oxidation of the agents by inhibitory effects of nilotinib, mainly on CYP3A4 activities, and of febuxostat on CYP2C8 activities.	repaglinide	20-31	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	341-347
33088647-7	2020	Repaglinide is eliminated by the liver, and is a short-acting insulin secretagogue with a good safety profile in patients with type 2 diabetes complicated by renal impairment, including elderly patients; however, its delayed elimination due to drug-drug interactions should be noted.	repaglinide	0-11	insulin	Homo sapiens	62-69
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	repaglinide	164-175	solute carrier organic anion transporter family member 1B1	Homo sapiens	82-89
32206324-2	2020	It has been suggested that the concomitant use of repaglinide with clopidogrel may inhibit repaglinide metabolism, because repaglinide is a substrate of cytochrome P450 2C8 (CYP2C8) and the main metabolite of clopidogrel acyl-beta-D-glucuronide inhibits CYP2C8 activity.	repaglinide	50-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	153-172
32206324-2	2020	It has been suggested that the concomitant use of repaglinide with clopidogrel may inhibit repaglinide metabolism, because repaglinide is a substrate of cytochrome P450 2C8 (CYP2C8) and the main metabolite of clopidogrel acyl-beta-D-glucuronide inhibits CYP2C8 activity.	repaglinide	50-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	174-180
32206324-2	2020	It has been suggested that the concomitant use of repaglinide with clopidogrel may inhibit repaglinide metabolism, because repaglinide is a substrate of cytochrome P450 2C8 (CYP2C8) and the main metabolite of clopidogrel acyl-beta-D-glucuronide inhibits CYP2C8 activity.	repaglinide	50-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	254-260
32206324-2	2020	It has been suggested that the concomitant use of repaglinide with clopidogrel may inhibit repaglinide metabolism, because repaglinide is a substrate of cytochrome P450 2C8 (CYP2C8) and the main metabolite of clopidogrel acyl-beta-D-glucuronide inhibits CYP2C8 activity.	repaglinide	91-102	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	174-180
32206324-2	2020	It has been suggested that the concomitant use of repaglinide with clopidogrel may inhibit repaglinide metabolism, because repaglinide is a substrate of cytochrome P450 2C8 (CYP2C8) and the main metabolite of clopidogrel acyl-beta-D-glucuronide inhibits CYP2C8 activity.	repaglinide	91-102	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	174-180
31861249-0	2019	Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells.	repaglinide	0-11	forkhead box O3	Homo sapiens	25-30
31861249-5	2019	By a drug-library screen we identified the small molecular weight compound repaglinide (RPG) as a putative FOXO3 inhibitor.	repaglinide	75-86	forkhead box O3	Homo sapiens	107-112
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	repaglinide	164-175	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
31129789-5	2019	METHODS: PBPK models of the CYP2C8 and organic-anion-transporting polypeptide (OATP) 1B1 perpetrator drug gemfibrozil (parent-metabolite model) and the CYP2C8 victim drugs repaglinide (also an OATP1B1 substrate) and pioglitazone were developed using a total of 103 clinical studies.	repaglinide	172-183	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	28-34
31452966-0	2019	Interaction of repaglinide with bovine serum albumin: Spectroscopic and molecular docking approaches.	repaglinide	15-26	albumin	Homo sapiens	39-52
31787898-0	2019	MTNR1B Gene Polymorphisms Are Associated With the Therapeutic Responses to Repaglinide in Chinese Patients With Type 2 Diabetes Mellitus.	repaglinide	75-86	melatonin receptor 1B	Homo sapiens	0-6
31787898-1	2019	The objective of this study was to investigate whether MTNR1B gene variants influence repaglinide response in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM).	repaglinide	86-97	melatonin receptor 1B	Homo sapiens	55-61
31787898-4	2019	After 8-week repaglinide monotherapy, patients with at least one G allele of MTNR1B rs10830963 showed a smaller decrease in fasting plasma glucose (FPG) (P = 0.031) and a smaller increase in homeostasis model assessment for beta cell function (HOMA-B) (P = 0.002) levels than those with the CC genotype did.	repaglinide	13-24	melatonin receptor 1B	Homo sapiens	77-83
31787898-6	2019	These data suggest that the MTNR1B rs10830963 and rs1387153 polymorphisms are associated with repaglinide monotherapy efficacy in Chinese patients with T2DM.	repaglinide	94-105	melatonin receptor 1B	Homo sapiens	28-34
31118371-0	2019	A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients.	repaglinide	78-89	ATP binding cassette subfamily C member 8	Homo sapiens	19-24
31118371-1	2019	Objective Previous studies have suggested that variations in the ABCC8 gene may be closely associated with T2DM susceptibility and repaglinide response.	repaglinide	131-142	ATP binding cassette subfamily C member 8	Homo sapiens	65-70
31118371-9	2019	Conclusion These results suggested that the ABCC8 rs1801261 polymorphism might influence T2DM susceptibility and the therapeutic effect of repaglinide in Chinese Han T2DM patients.	repaglinide	139-150	ATP binding cassette subfamily C member 8	Homo sapiens	44-49
31452966-1	2019	Repaglinide (RPG) regulates the amount of glucose by stimulating the pancreas to release insulin in the blood.	repaglinide	0-11	insulin	Homo sapiens	89-96
31452966-1	2019	Repaglinide (RPG) regulates the amount of glucose by stimulating the pancreas to release insulin in the blood.	repaglinide	13-16	insulin	Homo sapiens	89-96
31067468-1	2019	Repaglinide (RPG) is a short-acting insulin secretagogue widely prescribed for the treatment of type 2 diabetes.	repaglinide	0-11	insulin	Homo sapiens	36-43
31026357-6	2019	Attenuation of IL-1beta secretion by Nateglinide/Repaglinide further suggests involvement of Kir6 channels.	repaglinide	49-60	interleukin 1 beta	Homo sapiens	15-23
31086218-2	2019	We recently showed that reduced DREAM expression or blockade of DREAM activity by repaglinide is neuroprotective in Huntington"s disease (HD).	repaglinide	82-93	potassium voltage-gated channel interacting protein 3	Homo sapiens	32-37
31086218-2	2019	We recently showed that reduced DREAM expression or blockade of DREAM activity by repaglinide is neuroprotective in Huntington"s disease (HD).	repaglinide	82-93	potassium voltage-gated channel interacting protein 3	Homo sapiens	64-69
31086218-3	2019	Here we used structure-based drug design to guide the identification of IQM-PC330, which was more potent and had longer lasting effects than repaglinide to inhibit DREAM in cellular and in vivo HD models.	repaglinide	141-152	potassium voltage-gated channel interacting protein 3	Homo sapiens	164-169
31067468-1	2019	Repaglinide (RPG) is a short-acting insulin secretagogue widely prescribed for the treatment of type 2 diabetes.	repaglinide	13-16	insulin	Homo sapiens	36-43
30636597-0	2019	Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.	repaglinide	55-66	solute carrier organic anion transporter family member 1B1	Homo sapiens	22-29
30833929-10	2019	Insulin secretagogue agents have to be used with caution because of their significant hypoglycemic risk; if used, short-acting sulfonylureas, as gliclazide, or glinides as repaglinide, should be preferred.	repaglinide	172-183	insulin	Homo sapiens	0-7
29901213-4	2019	The model was then used to prospectively predict the interaction between letermovir and CYP2C8 substrates such as repaglinide, a substrate of CYP2C8, CYP3A, and OATP1B.	repaglinide	114-125	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	88-94
29901213-4	2019	The model was then used to prospectively predict the interaction between letermovir and CYP2C8 substrates such as repaglinide, a substrate of CYP2C8, CYP3A, and OATP1B.	repaglinide	114-125	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	142-148
29901213-4	2019	The model was then used to prospectively predict the interaction between letermovir and CYP2C8 substrates such as repaglinide, a substrate of CYP2C8, CYP3A, and OATP1B.	repaglinide	114-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-155
30636597-1	2019	OBJECTIVE: The purpose of this systematic review and meta-analysis was to summarize the potential impact of CYP2C8 and SLCO1B1 genetic polymorphisms on repaglinide pharmacokinetics.	repaglinide	152-163	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	108-114
30636597-1	2019	OBJECTIVE: The purpose of this systematic review and meta-analysis was to summarize the potential impact of CYP2C8 and SLCO1B1 genetic polymorphisms on repaglinide pharmacokinetics.	repaglinide	152-163	solute carrier organic anion transporter family member 1B1	Homo sapiens	119-126
30636597-10	2019	CONCLUSION: The current systematic review and meta-analysis indicated that the genotype of CYP2C8, but not SLCO1B1, may affect repaglinide pharmacokinetics.	repaglinide	127-138	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	91-97
31089348-0	2019	An Investigation into the Role of P-Glycoprotein in the Intestinal Absorption of Repaglinide: Assessed by Everted Gut Sac and Caco-2 Cell Line.	repaglinide	81-92	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
31122183-7	2019	RESULTS: SLCs and AMPK variations are considered for metformin, CYP2C9, KATP channel, CDKAL1, CDKN2A/2B and KCNQ1 for sulphonylureas, OATP1B, and KCNQ1 for repaglinide and the last but not the least ADIPOQ, PPAR-gamma, SLC, CYP2C8, and SLCO1B1 for thiazolidinediones response prediction.	repaglinide	156-167	C-C motif chemokine ligand 21	Homo sapiens	9-12
31089348-1	2019	The present study aimed at exploring the potential of the P-glycoprotein (P-gp) transporters as a barrier to the repaglinide (REG) epithelial permeability.	repaglinide	113-124	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
31089348-1	2019	The present study aimed at exploring the potential of the P-glycoprotein (P-gp) transporters as a barrier to the repaglinide (REG) epithelial permeability.	repaglinide	113-124	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
30559648-3	2018	Small-molecules able to bind DREAM, like the anti-diabetic drug repaglinide, disrupt some of the interactions with other proteins and modulate DREAM activity on Kv4 channels or on the processing of activating transcription factor 6 (ATF6).	repaglinide	64-75	Kv channel interacting protein 3, calsenilin	Mus musculus	29-34
30559648-3	2018	Small-molecules able to bind DREAM, like the anti-diabetic drug repaglinide, disrupt some of the interactions with other proteins and modulate DREAM activity on Kv4 channels or on the processing of activating transcription factor 6 (ATF6).	repaglinide	64-75	Kv channel interacting protein 3, calsenilin	Mus musculus	143-148
30559648-3	2018	Small-molecules able to bind DREAM, like the anti-diabetic drug repaglinide, disrupt some of the interactions with other proteins and modulate DREAM activity on Kv4 channels or on the processing of activating transcription factor 6 (ATF6).	repaglinide	64-75	activating transcription factor 6	Mus musculus	198-231
30559648-3	2018	Small-molecules able to bind DREAM, like the anti-diabetic drug repaglinide, disrupt some of the interactions with other proteins and modulate DREAM activity on Kv4 channels or on the processing of activating transcription factor 6 (ATF6).	repaglinide	64-75	activating transcription factor 6	Mus musculus	233-237
30559648-5	2018	We show that repaglinide disrupts the interaction between DREAM and the C-terminal PS2 fragment (Ct-PS2) by coimmunoprecipitation assays.	repaglinide	13-24	Kv channel interacting protein 3, calsenilin	Mus musculus	58-63
30559648-5	2018	We show that repaglinide disrupts the interaction between DREAM and the C-terminal PS2 fragment (Ct-PS2) by coimmunoprecipitation assays.	repaglinide	13-24	presenilin 2	Mus musculus	83-86
30559648-5	2018	We show that repaglinide disrupts the interaction between DREAM and the C-terminal PS2 fragment (Ct-PS2) by coimmunoprecipitation assays.	repaglinide	13-24	cytidine 5'-triphosphate synthase 2	Mus musculus	97-103
30559648-6	2018	Exposure to sub-micromolar concentrations of repaglinide reduces the levels of Ct-PS2 fragment in N2a neuroblastoma cells.	repaglinide	45-56	cytidine 5'-triphosphate synthase 2	Mus musculus	79-85
30260092-5	2018	The clearance of atorvastatin and repaglinide had a strong correlation (r2  = 0.70 and 0.63, respectively) with that of pitavastatin (a SLCO1B1 probe).	repaglinide	34-45	solute carrier organic anion transporter family member 1B1	Homo sapiens	136-143
30235745-0	2018	Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.	repaglinide	19-30	insulin	Homo sapiens	62-69
30235745-1	2018	This study aims to compare the effect of repaglinide and metformin among Chinese patients with newly diagnosed diabetes, and explore the possible mechanisms by which repaglinide alters insulin secretion.Sixty subjects with glycated hemoglobin (HbA1c) < 10.0% were randomly selected to receive repaglinide or metformin monotherapy for 15 weeks.	repaglinide	166-177	insulin	Homo sapiens	185-192
30213010-13	2018	After 4 months, the patient showed liver injury once again (an increase in ALT, AST, AKP, GGT and GLB) caused by repaglinide administration due to hyperglycemia.	repaglinide	113-124	solute carrier family 17 member 5	Homo sapiens	80-83
30235745-1	2018	This study aims to compare the effect of repaglinide and metformin among Chinese patients with newly diagnosed diabetes, and explore the possible mechanisms by which repaglinide alters insulin secretion.Sixty subjects with glycated hemoglobin (HbA1c) < 10.0% were randomly selected to receive repaglinide or metformin monotherapy for 15 weeks.	repaglinide	166-177	insulin	Homo sapiens	185-192
30235745-8	2018	Insulin, PCNT, and F-actin expression in MIN-6 cells decreased after 15 minutes of stimulation with repaglinide, while no difference was observed at 2, 6, and 12 hours.	repaglinide	100-111	insulin	Homo sapiens	0-7
30235745-8	2018	Insulin, PCNT, and F-actin expression in MIN-6 cells decreased after 15 minutes of stimulation with repaglinide, while no difference was observed at 2, 6, and 12 hours.	repaglinide	100-111	pericentrin (kendrin)	Mus musculus	9-13
30235745-9	2018	The insulin levels of the cell medium in the repaglinide group remained significantly higher at all timepoints.This study manifests that repaglinide has a noninferiority effect on the glycemic parameters of Chinese patients with newly diagnosed diabetes, when compared with metformin.	repaglinide	45-56	insulin	Homo sapiens	4-11
30235745-10	2018	The PCNT-F-actin pathway plays an important role in the repaglinide regulation process of on-demand insulin secretion.	repaglinide	56-67	pericentrin	Homo sapiens	4-8
30235745-10	2018	The PCNT-F-actin pathway plays an important role in the repaglinide regulation process of on-demand insulin secretion.	repaglinide	56-67	insulin	Homo sapiens	100-107
29663513-0	2018	A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.	repaglinide	65-76	G protein-coupled receptor kinase 5	Homo sapiens	13-17
29381228-2	2018	We investigate, as an example, the impact of CYP3A4-CYP2C8 intercorrelation on the predicted interindividual variabilities of clearance and drug-drug interactions (DDIs) for repaglinide using physiologically based pharmacokinetic (PBPK) modelling.	repaglinide	174-185	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	52-58
30121055-0	2018	Repaglinide inhibits cyclosporine A-induced renal tubular toxicityby affecting apoptosis and Baxand Bcl-2expression Background/aim: Repaglinide (RG) is a prandial glucose regulator used for the treatment of type 2 diabetes.	repaglinide	0-11	BCL2, apoptosis regulator	Rattus norvegicus	100-105
30121055-0	2018	Repaglinide inhibits cyclosporine A-induced renal tubular toxicityby affecting apoptosis and Baxand Bcl-2expression Background/aim: Repaglinide (RG) is a prandial glucose regulator used for the treatment of type 2 diabetes.	repaglinide	132-143	BCL2, apoptosis regulator	Rattus norvegicus	100-105
29748863-0	2018	Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.	repaglinide	0-11	solute carrier organic anion transporter family member 1B1	Homo sapiens	52-59
29748863-5	2018	Clinical data from single dose of repaglinide indicated SLCO1B1 c.521 T>C polymorphism influenced the PK and PD of repaglinide in healthy Chinese-Han male volunteers.	repaglinide	34-45	solute carrier organic anion transporter family member 1B1	Homo sapiens	56-63
29748863-5	2018	Clinical data from single dose of repaglinide indicated SLCO1B1 c.521 T>C polymorphism influenced the PK and PD of repaglinide in healthy Chinese-Han male volunteers.	repaglinide	118-129	solute carrier organic anion transporter family member 1B1	Homo sapiens	56-63
29748863-9	2018	CONCLUSION: SLCO1B1 c.521 T>C polymorphism affects the PK of repaglinide in Chinese population.	repaglinide	64-75	solute carrier organic anion transporter family member 1B1	Homo sapiens	12-19
29748863-10	2018	Irbesartan increased repaglinide exposure in subjects with SLCO1B1 c.521 TT genotype, but not SLCO1B1 c.521 TC genotype.	repaglinide	21-32	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-66
29555503-3	2018	In the presence of glucagon-like peptide-1 (GLP-1), insulin secretion by repaglinide was augmented significantly but to lesser extent and showed different dynamics from that by glimepiride.	repaglinide	73-84	glucagon	Homo sapiens	19-42
29555503-3	2018	In the presence of glucagon-like peptide-1 (GLP-1), insulin secretion by repaglinide was augmented significantly but to lesser extent and showed different dynamics from that by glimepiride.	repaglinide	73-84	glucagon	Homo sapiens	44-49
29555503-8	2018	Our data indicate that repaglinide has characteristic properties in its effects on the dynamics of insulin secretion and intracellular Ca2+ and that the combination of repaglinide and GLP-1 stimulates insulin secretion more effectively than the combination of glimepiride and GLP-1 at a high concentration of glucose, providing a basis for its use in clinical settings.	repaglinide	23-34	glucagon	Homo sapiens	276-281
29663513-1	2018	Post-Market Research We aimed to investigate the impact of G protein-coupled receptor kinase 5 (GRK5) rs10886471 polymorphism on repaglinide efficacy in Chinese patients with type 2 diabetes mellitus (T2DM).	repaglinide	129-140	G protein-coupled receptor kinase 5	Homo sapiens	59-94
29663513-1	2018	Post-Market Research We aimed to investigate the impact of G protein-coupled receptor kinase 5 (GRK5) rs10886471 polymorphism on repaglinide efficacy in Chinese patients with type 2 diabetes mellitus (T2DM).	repaglinide	129-140	G protein-coupled receptor kinase 5	Homo sapiens	96-100
29663513-8	2018	These findings suggest that GRK5 rs10886471 polymorphism may influence the therapeutic efficacy of repaglinide in Chinese Han T2DM patients.	repaglinide	99-110	G protein-coupled receptor kinase 5	Homo sapiens	28-32
28476618-8	2017	Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling.	repaglinide	123-134	beclin 1	Homo sapiens	58-66
29523177-5	2018	Using the novel object recognition test, we show that chronic administration of the DREAM-binding molecule repaglinide, or induced DREAM haplodeficiency delays onset of cognitive impairment in R6/1 mice, another HD model.	repaglinide	107-118	Kv channel interacting protein 3, calsenilin	Mus musculus	84-89
29523177-6	2018	The mechanism involves a notable rise in the levels of transcriptionally active ATF6 protein in the hippocampus after repaglinide administration.	repaglinide	118-129	activating transcription factor 6	Mus musculus	80-84
28653847-5	2017	As interaction perpetrators with CYP2C8, glucuronides of gemfibrozil and clopidogrel showed marked clinical drug-drug interactions (e.g., with cerivastatin and repaglinide), which are more than expected from the parent drug.	repaglinide	160-171	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	33-39
28479356-2	2017	Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4.	repaglinide	0-11	solute carrier organic anion transporter family member 1B1	Homo sapiens	51-58
28479356-2	2017	Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	86-92
28479356-2	2017	Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4.	repaglinide	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
28479356-2	2017	Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4.	repaglinide	13-16	solute carrier organic anion transporter family member 1B1	Homo sapiens	51-58
28479356-2	2017	Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4.	repaglinide	13-16	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	86-92
28479356-2	2017	Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4.	repaglinide	13-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
28977924-10	2017	The percentage of patients with low eGFR (i.e. <30 ml/min/1.73m2) taking either metformin or sulphonilureas/repaglinide was particularly high (i.e. 15.3% and 34.3% respectively).	repaglinide	111-122	epidermal growth factor receptor	Homo sapiens	36-40
28653144-8	2018	RESULTS: Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.	repaglinide	208-219	solute carrier organic anion transporter family member 1B1	Homo sapiens	73-80
28653144-8	2018	RESULTS: Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.	repaglinide	208-219	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-90
28238899-0	2017	Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.	repaglinide	55-66	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	34-40
28238899-0	2017	Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.	repaglinide	55-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
28238899-2	2017	In the present study, therefore, the possibility of buffer condition dependence of the fraction metabolized by CYP2C8 (fm2C8) for repaglinide, a dual substrate of CYP2C8 and CYP3A4, was estimated using human liver microsomes under various buffer conditions.	repaglinide	130-141	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	111-117
28238899-2	2017	In the present study, therefore, the possibility of buffer condition dependence of the fraction metabolized by CYP2C8 (fm2C8) for repaglinide, a dual substrate of CYP2C8 and CYP3A4, was estimated using human liver microsomes under various buffer conditions.	repaglinide	130-141	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	163-169
28238899-2	2017	In the present study, therefore, the possibility of buffer condition dependence of the fraction metabolized by CYP2C8 (fm2C8) for repaglinide, a dual substrate of CYP2C8 and CYP3A4, was estimated using human liver microsomes under various buffer conditions.	repaglinide	130-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
28238899-5	2017	Based on these results, the contribution of CYP2C8 in repaglinide metabolism was estimated to be larger than that of CYP3A4 under each buffer condition, and the fm2C8 value of 0.760, estimated in 50 mM phosphate buffer, was the closest to the value (0.801) estimated in our previous modeling analysis based on its concentration increase in a clinical drug interaction study.	repaglinide	54-65	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	44-50
28476618-8	2017	Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling.	repaglinide	17-28	BCL2 apoptosis regulator	Homo sapiens	51-56
28476618-8	2017	Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling.	repaglinide	17-28	beclin 1	Homo sapiens	58-66
28476618-8	2017	Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling.	repaglinide	17-28	CD274 molecule	Homo sapiens	71-76
28476618-8	2017	Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling.	repaglinide	123-134	BCL2 apoptosis regulator	Homo sapiens	51-56
28476618-8	2017	Mechanistically, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling.	repaglinide	123-134	CD274 molecule	Homo sapiens	71-76
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	repaglinide	155-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
31149163-7	2017	Focusing on 4 patients who received DPP-4 inhibitor monotherapy at enrolment, switching to repaglinide also significantly improved HbA1c levels.	repaglinide	91-102	dipeptidyl peptidase 4	Homo sapiens	36-41
31149163-10	2017	In case that DPP-4 inhibitors are not enough to achieve targeted range of glycemic control, repaglinide is another good candidate.	repaglinide	92-103	dipeptidyl peptidase 4	Homo sapiens	13-18
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	repaglinide	155-166	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	136-142
27543206-8	2016	Finally, incorporation of protein expression of OATP1B1 in alcoholic cirrhosis into the Simcyp physiologically based pharmacokinetics cirrhosis module improved prediction of the disposition of repaglinide in liver cirrhosis patients.	repaglinide	193-204	solute carrier organic anion transporter family member 1B1	Homo sapiens	48-55
27967230-10	2017	Noninsulin antidiabetes agents like dipeptidyl peptidase 4 inhibitors, repaglinide, and glipizide in appropriate doses and reduction of insulin doses up to 50% may help decrease hypoglycemia.	repaglinide	71-82	insulin	Homo sapiens	3-10
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	repaglinide	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27857189-0	2016	A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.	repaglinide	45-56	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	15-20
27857189-0	2016	A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.	repaglinide	45-56	insulin	Homo sapiens	69-76
27857189-1	2016	Repaglinide is an insulin secretagogue that often exhibits considerable interindividual variability in therapeutic efficacy.	repaglinide	0-11	insulin	Homo sapiens	18-25
27857189-2	2016	The current study was designed to investigate the impact of KCNQ1 genetic polymorphism on the efficacy of repaglinide and furthermore to identify the potential mechanism of action in patients with type 2 diabetes.	repaglinide	106-117	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	60-65
27857189-7	2016	The KCNQ1 inhibitor enhanced repaglinide efficacy on insulin resistance, with IRS-2/PI(3)K/Akt signaling being up-regulated markedly.	repaglinide	29-40	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	4-9
27857189-7	2016	The KCNQ1 inhibitor enhanced repaglinide efficacy on insulin resistance, with IRS-2/PI(3)K/Akt signaling being up-regulated markedly.	repaglinide	29-40	insulin	Homo sapiens	53-60
27857189-8	2016	As in our clinical experiment, these data strongly suggest that KCNQ1 genetic polymorphism influences repaglinide response due to the pivotal role of KCNQ1 in regulating insulin resistance through the IRS-2/PI(3)K/Akt signaling pathway.	repaglinide	102-113	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	64-69
27857189-8	2016	As in our clinical experiment, these data strongly suggest that KCNQ1 genetic polymorphism influences repaglinide response due to the pivotal role of KCNQ1 in regulating insulin resistance through the IRS-2/PI(3)K/Akt signaling pathway.	repaglinide	102-113	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	150-155
27857189-8	2016	As in our clinical experiment, these data strongly suggest that KCNQ1 genetic polymorphism influences repaglinide response due to the pivotal role of KCNQ1 in regulating insulin resistance through the IRS-2/PI(3)K/Akt signaling pathway.	repaglinide	102-113	insulin	Homo sapiens	170-177
27857189-8	2016	As in our clinical experiment, these data strongly suggest that KCNQ1 genetic polymorphism influences repaglinide response due to the pivotal role of KCNQ1 in regulating insulin resistance through the IRS-2/PI(3)K/Akt signaling pathway.	repaglinide	102-113	insulin receptor substrate 2	Homo sapiens	201-206
27857189-8	2016	As in our clinical experiment, these data strongly suggest that KCNQ1 genetic polymorphism influences repaglinide response due to the pivotal role of KCNQ1 in regulating insulin resistance through the IRS-2/PI(3)K/Akt signaling pathway.	repaglinide	102-113	AKT serine/threonine kinase 1	Homo sapiens	214-217
27435474-10	2016	Based on these results, we conclude that repaglinide induces vasorelaxation via activation of adenylyl cyclase/PKA and guanylyl cyclase/PKG signaling pathways independently of the endothelium, K(+) channels, Ca(2+) channels, and intracellular Ca(2+) ([Ca(2+)]i).	repaglinide	41-52	protein kinase cGMP-dependent 1	Homo sapiens	136-139
27457785-6	2016	The predicted AUCRs using the mechanism-based inhibition of CYP2C8 by clopidogrel acyl-beta-glucuronide were similar to the observed AUCRs, and the predicted AUCR (1.1) of repaglinide using only the inhibition of OATP1B1 did not reach the observed AUCR (3.1).	repaglinide	172-183	solute carrier organic anion transporter family member 1B1	Homo sapiens	213-220
27457785-8	2016	Clopidogrel is expected to have an effect not only on CYP2C8 substrates, but also dual CYP2C8/OATP1B1 substrates as seen in the case of repaglinide.	repaglinide	136-147	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	87-93
27457785-8	2016	Clopidogrel is expected to have an effect not only on CYP2C8 substrates, but also dual CYP2C8/OATP1B1 substrates as seen in the case of repaglinide.	repaglinide	136-147	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-101
27435474-0	2016	The anti-diabetic drug repaglinide induces vasorelaxation via activation of PKA and PKG in aortic smooth muscle.	repaglinide	23-34	protein kinase cGMP-dependent 1	Homo sapiens	84-87
27435474-6	2016	Also, pretreatment with a guanylyl cyclase inhibitor (ODQ) or a PKG inhibitor (KT 5823) inhibited repaglinide-induced vasorelaxation.	repaglinide	98-109	protein kinase cGMP-dependent 1	Homo sapiens	64-67
27042279-1	2016	AIMS/INTRODUCTION: The aim of the present study was to evaluate the long-term efficacy and safety of adding repaglinide in patients with type 2 diabetes mellitus whose blood glucose levels were not sufficiently controlled by treatment with a dipeptidyl peptidase-4 inhibitor, sitagliptin, in addition to diet and exercise therapies.	repaglinide	108-119	dipeptidyl peptidase 4	Homo sapiens	242-264
27259818-0	2016	CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.	repaglinide	36-47	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
27259818-4	2016	SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3"-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 muM and 11.6 muM, respectively.	repaglinide	52-63	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	36-42
26883446-6	2016	Repaglinide also had some positive influence on HUVEC function elevating NO production in the presence of VEGF.	repaglinide	0-11	vascular endothelial growth factor A	Homo sapiens	106-110
26752648-6	2016	Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons.	repaglinide	0-11	activating transcription factor 6	Mus musculus	50-54
26752648-6	2016	Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons.	repaglinide	0-11	activating transcription factor 6	Mus musculus	119-123
26548081-4	2015	In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model.	repaglinide	200-211	insulin	Homo sapiens	159-166
26296069-1	2015	PURPOSE: Repaglinide and pioglitazone are both CYP2C8 and CYP3A4 substrates.	repaglinide	9-20	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	47-53
26296069-1	2015	PURPOSE: Repaglinide and pioglitazone are both CYP2C8 and CYP3A4 substrates.	repaglinide	9-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
25862064-9	2015	A photo-induced cross-linking-based oligomerization assay demonstrated that repaglinide supressed the formation of hIAPP oligomers, whereas glyburide and troglitazone were ineffective in inhibiting oligomerization.	repaglinide	76-87	islet amyloid polypeptide	Homo sapiens	115-120
26692235-1	2016	CONTEXT: Repaglinide is a short-acting insulin secretagogue with high interindividual variability in pharmacokinetics due to genetic polymorphisms.	repaglinide	9-20	insulin	Homo sapiens	39-46
26721703-3	2016	CYP2C8 substrate drugs include amodiaquine, cerivastatin, dasabuvir, enzalutamide, imatinib, loperamide, montelukast, paclitaxel, pioglitazone, repaglinide, and rosiglitazone, and the number is increasing.	repaglinide	144-155	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
25595597-6	2015	Other inhibitors of CYP2C8 (gemfibrozil, montelukast, clopidogrel glucuronide, repaglinide, and cerivastatin) also caused extensive inhibition of 3-hydroxydesloratadine formation (73%-100%).	repaglinide	79-90	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
26013675-4	2015	RESULTS: Increased risks of HCC were found for use of insulin (odds ratio [OR] = 3.73, 95% confidence interval [CI] 2.52-5.51), sulfonylureas (OR = 1.39, 95%CI 0.98-1.99), and repaglinide (OR = 2.12, 95%CI 1.38-3.26), while a reduced risk was found for use of metformin (OR = 0.57, 95%CI 0.41-0.79).	repaglinide	176-187	insulin	Homo sapiens	54-61
26013675-5	2015	The risk of HCC increased with increasing duration of insulin use (OR = 2.52 for <1 year, 5.41 for 1-2 years, and 6.01 for >=2 years; p for trend < 0.001), while no clear pattern with duration was observed for sulfonylureas, repaglinide, and metformin.	repaglinide	234-245	insulin	Homo sapiens	54-61
26024304-7	2015	In the repaglinide cohort, rs831571 was significantly associated with decreased HbA1c levels after 24 weeks of treatment, the homeostatic model assessment of insulin resistance and fasting insulin level after 48 weeks of treatment with repaglinide (P = 0.0096, 0235 and 0.0212, respectively).	repaglinide	7-18	insulin	Homo sapiens	189-196
26024304-7	2015	In the repaglinide cohort, rs831571 was significantly associated with decreased HbA1c levels after 24 weeks of treatment, the homeostatic model assessment of insulin resistance and fasting insulin level after 48 weeks of treatment with repaglinide (P = 0.0096, 0235 and 0.0212, respectively).	repaglinide	236-247	insulin	Homo sapiens	189-196
26024304-8	2015	In conclusion, we observed that the PSMD6 variant rs831571 might be associated with the therapeutic effects of rosiglitazone and repaglinide in Chinese T2DM patients.	repaglinide	129-140	proteasome 26S subunit, non-ATPase 6	Homo sapiens	36-41
24704461-0	2014	Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.	repaglinide	27-38	carbonic anhydrase 3	Mus musculus	85-88
24971633-1	2014	Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1.	repaglinide	17-28	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	47-71
24971633-1	2014	Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1.	repaglinide	17-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
24971633-1	2014	Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1.	repaglinide	17-28	solute carrier organic anion transporter family member 1B1	Homo sapiens	85-133
24843385-10	2014	The levels of plasminogen activator inhibitor-1, high sensitivity C-reactive protein, and urinary 8-hydoroxydeoxyguanosine were reduced significantly by repaglinide treatment.	repaglinide	153-164	serpin family E member 1	Homo sapiens	14-47
24843385-10	2014	The levels of plasminogen activator inhibitor-1, high sensitivity C-reactive protein, and urinary 8-hydoroxydeoxyguanosine were reduced significantly by repaglinide treatment.	repaglinide	153-164	C-reactive protein	Homo sapiens	66-84
25311380-0	2015	PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.	repaglinide	37-48	peroxisome proliferator activated receptor delta	Homo sapiens	0-5
25311380-1	2015	Repaglinide is a short-acting insulin secretagogue, which often results in considerable interindividual variability in therapeutic efficacy when widely used in a clinical setting.	repaglinide	0-11	insulin	Homo sapiens	30-37
25311380-4	2015	However, little is known about the impacts of PPARD genetic polymorphism on the efficacy of repaglinide.	repaglinide	92-103	peroxisome proliferator activated receptor delta	Homo sapiens	46-51
25311380-5	2015	Therefore, the current study was designed to investigate the associations of PPARD rs2016520 polymorphism with type 2 diabetes mellitus (T2DM) susceptibility and repaglinide therapeutic efficacy in Chinese Han T2DM patients.	repaglinide	162-173	peroxisome proliferator activated receptor delta	Homo sapiens	77-82
25311380-11	2015	These findings suggest that PPARD rs2016520 polymorphism might influence the therapeutic effect of repaglinide rather than T2DM susceptibility in Chinese Han T2DM patients.	repaglinide	99-110	peroxisome proliferator activated receptor delta	Homo sapiens	28-33
25560470-1	2015	Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels.	repaglinide	20-31	insulin	Homo sapiens	84-91
25560470-1	2015	Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels.	repaglinide	20-31	insulin	Homo sapiens	142-149
24623479-1	2014	PURPOSE: To investigate the effect of OATP1B1 genotype as a covariate on repaglinide pharmacokinetics and drug-drug interaction (DDIs) risk using a reduced physiologically-based pharmacokinetic (PBPK) model.	repaglinide	73-84	solute carrier organic anion transporter family member 1B1	Homo sapiens	38-45
24623479-3	2014	RESULTS: Estimated repaglinide CLuptake corresponded to 217 and 113 muL/min/10(6) cells for SLCO1B1 c.521TT/TC and CC, respectively.	repaglinide	19-30	solute carrier organic anion transporter family member 1B1	Homo sapiens	92-99
24623479-6	2014	Propagation of this uncertainty had a marginal effect on the prediction of repaglinide OATP1B1-mediated DDI with cyclosporine; however, sensitivity of the predicted magnitude of repaglinide metabolic DDI was high.	repaglinide	75-86	solute carrier organic anion transporter family member 1B1	Homo sapiens	87-94
24623479-7	2014	In addition, the reduced PBPK model was used to assess the effect of both CYP2C8*3 and SLCO1B1 c.521T>C on repaglinide exposure by simulations; power calculations were performed to guide prospective DDI and pharmacogenetic studies.	repaglinide	110-121	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
24623479-7	2014	In addition, the reduced PBPK model was used to assess the effect of both CYP2C8*3 and SLCO1B1 c.521T>C on repaglinide exposure by simulations; power calculations were performed to guide prospective DDI and pharmacogenetic studies.	repaglinide	110-121	solute carrier organic anion transporter family member 1B1	Homo sapiens	87-94
24704461-8	2014	pretreatment with repaglinide attenuated the KA-induced neuronal cell death in CA3 region of the hippocampus and hyperglycemia.	repaglinide	18-29	carbonic anhydrase 3	Mus musculus	79-82
24704461-18	2014	Our results suggest that supraspinally administered repaglinide, but not nateglinide, exerts a protective effect against the KA-induced neuronal cells death in CA3 region of the hippocampus.	repaglinide	52-63	carbonic anhydrase 3	Mus musculus	160-163
24338736-0	2014	Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.	repaglinide	45-56	nitric oxide synthase 1 adaptor protein	Homo sapiens	11-17
24567025-11	2014	After the HNF1A-MODY diagnosis, treatment was changed to repaglinide.	repaglinide	57-68	HNF1 homeobox A	Homo sapiens	10-15
24338736-11	2014	The effects of repaglinide treatment on FPG (p<0.01), FINS (p<0.05) and HOMA-IR (p<0.001) were reduced in patients with T2DM carrying the NOS1AP rs12742393 risk C allele compared with the AA genotype carriers.	repaglinide	15-26	nitric oxide synthase 1 adaptor protein	Homo sapiens	147-153
24338736-12	2014	CONCLUSION: The NOS1AP rs12742393 polymorphism is associated with therapeutic efficacy of repaglinide in Chinese T2DM patients.	repaglinide	90-101	nitric oxide synthase 1 adaptor protein	Homo sapiens	16-22
24338736-1	2014	STUDY OBJECTIVE: To investigate the associations of NOS1AP rs12742393 polymorphism with the risk of type 2 diabetes mellitus (T2DM) and repaglinide therapeutic efficacy in Chinese patients with T2DM.	repaglinide	136-147	nitric oxide synthase 1 adaptor protein	Homo sapiens	52-58
23807564-0	2013	PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers.	repaglinide	75-86	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
23807564-5	2013	Thus, a clinical study in healthy Chinese subjects was conducted to investigate the impact of PXR polymorphisms on repaglinide (an endogenous marker for CYP3A4 activity) pharmacokinetics used alone or in combination with a PXR inducer, flucloxacillin.	repaglinide	115-126	nuclear receptor subfamily 1 group I member 2	Homo sapiens	94-97
23807564-5	2013	Thus, a clinical study in healthy Chinese subjects was conducted to investigate the impact of PXR polymorphisms on repaglinide (an endogenous marker for CYP3A4 activity) pharmacokinetics used alone or in combination with a PXR inducer, flucloxacillin.	repaglinide	115-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-159
23807564-13	2013	CONCLUSION: Our study results demonstrated for the first time the impact of genetic polymorphisms of PXR on the PK and PD of repaglinide, and showed that subjects with genotype of -298G/G and 11193C/C in PXR has a decreased elimination rate of 3A4/2C8.	repaglinide	125-136	nuclear receptor subfamily 1 group I member 2	Homo sapiens	101-104
23807564-13	2013	CONCLUSION: Our study results demonstrated for the first time the impact of genetic polymorphisms of PXR on the PK and PD of repaglinide, and showed that subjects with genotype of -298G/G and 11193C/C in PXR has a decreased elimination rate of 3A4/2C8.	repaglinide	125-136	nuclear receptor subfamily 1 group I member 2	Homo sapiens	204-207
24399740-11	2013	CONCLUSION: Nifedipine enhanced the oral bioavailability of repaglinide, which may be mainly attributable to inhibition of CYP3A4-mediated metabolism of repaglinide in the small intestine and/or in the liver and to inhibition of the P-gp efflux transporter in the small intestine and/or reduction of total body clearance by nifedipine.	repaglinide	60-71	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	233-237
23536207-1	2013	CYP2C8 plays an important role in the metabolism of various drugs, such as paclitaxel, repaglinide and ibuprofen.	repaglinide	87-98	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
23536207-2	2013	Polymorphisms in the CYP2C8 gene were shown to influence interindividual differences in the pharmacokinetics of paclitaxel, repaglinide and ibuprofen enantiomers.	repaglinide	124-135	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
23536207-6	2013	The CLint values of CYP2C8.2 and CYP2C8.4 for repaglinide were 77.9% and 80.2% of that of CYP2C8.1 (p<0.05), respectively, while the CLint value of CYP2C8.3 was 1.31-fold higher than that of CYP2C8.1 (p<0.05).	repaglinide	46-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
23536207-6	2013	The CLint values of CYP2C8.2 and CYP2C8.4 for repaglinide were 77.9% and 80.2% of that of CYP2C8.1 (p<0.05), respectively, while the CLint value of CYP2C8.3 was 1.31-fold higher than that of CYP2C8.1 (p<0.05).	repaglinide	46-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	33-39
23536207-6	2013	The CLint values of CYP2C8.2 and CYP2C8.4 for repaglinide were 77.9% and 80.2% of that of CYP2C8.1 (p<0.05), respectively, while the CLint value of CYP2C8.3 was 1.31-fold higher than that of CYP2C8.1 (p<0.05).	repaglinide	46-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	90-98
23536207-6	2013	The CLint values of CYP2C8.2 and CYP2C8.4 for repaglinide were 77.9% and 80.2% of that of CYP2C8.1 (p<0.05), respectively, while the CLint value of CYP2C8.3 was 1.31-fold higher than that of CYP2C8.1 (p<0.05).	repaglinide	46-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	33-39
23536207-6	2013	The CLint values of CYP2C8.2 and CYP2C8.4 for repaglinide were 77.9% and 80.2% of that of CYP2C8.1 (p<0.05), respectively, while the CLint value of CYP2C8.3 was 1.31-fold higher than that of CYP2C8.1 (p<0.05).	repaglinide	46-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	194-202
23536207-8	2013	Comparing hydroxylation by CYP2C8.1 and CYP2C8.3 resulted in higher and lower intrinsic clearance of repaglinide and ibuprofen enantiomers, respectively.	repaglinide	101-112	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	27-35
23536207-8	2013	Comparing hydroxylation by CYP2C8.1 and CYP2C8.3 resulted in higher and lower intrinsic clearance of repaglinide and ibuprofen enantiomers, respectively.	repaglinide	101-112	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	27-33
23393219-0	2013	Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.	repaglinide	27-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
23393219-1	2013	Repaglinide is mainly metabolized by cytochrome P450 enzymes CYP2C8 and CYP3A4, and it is also a substrate to a hepatic uptake transporter, organic anion transporting polypeptide (OATP)1B1.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	61-67
23393219-1	2013	Repaglinide is mainly metabolized by cytochrome P450 enzymes CYP2C8 and CYP3A4, and it is also a substrate to a hepatic uptake transporter, organic anion transporting polypeptide (OATP)1B1.	repaglinide	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
23393219-1	2013	Repaglinide is mainly metabolized by cytochrome P450 enzymes CYP2C8 and CYP3A4, and it is also a substrate to a hepatic uptake transporter, organic anion transporting polypeptide (OATP)1B1.	repaglinide	0-11	solute carrier organic anion transporter family member 1B1	Homo sapiens	180-188
23625433-1	2013	The effect of pitavastatin and SLCO1B1 genetic background on the pharmacokinetic and pharmacodynamic properties of repaglinide was investigated.	repaglinide	115-126	solute carrier organic anion transporter family member 1B1	Homo sapiens	31-38
23625433-4	2013	Treatment with pitavastatin significantly increased the peak plasma concentration (Cmax) of repaglinide (P=0.003) in SLCO1B1*1b homozygotes (P=0.015) and SLCO1B1*15 carriers (P=0.031).	repaglinide	92-103	solute carrier organic anion transporter family member 1B1	Homo sapiens	117-124
23625433-7	2013	Pitavastatin increased the Cmax of the plasma concentration of repaglinide in an SLCO1B1 genotype dependent manner, but had no apparent effect on the pharmacodynamics of repaglinide in healthy volunteers.	repaglinide	63-74	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
23526382-13	2013	This study showed the usefulness of CGMS not only as a diagnostic but also as an educational and therapeutic tool that in combination with Repaglinide (with the lowest effective dose and duration) can significantly reduce FBG and glycemic excursions in DM2 patients and hypoglycemic events are low.	repaglinide	139-150	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	253-256
23536207-0	2013	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.	repaglinide	81-92	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	13-19
23776402-13	2013	Fluvastatin enhanced the oral BA of repaglinide, which may be mainly attributable to the inhibition of the CYP3A4-mediated metabolism of repaglinide in the small intestine and/or liver, to the inhibition of the P-gp efflux transporter in the small intestine and/or to the reduction of TBC of repaglinide by fluvastatin.	repaglinide	36-47	phosphoglycolate phosphatase	Rattus norvegicus	211-215
22451699-1	2012	Repaglinide is presently recommended by the U.S. Food and Drug Administration as a clinical CYP2C8 probe, yet current in vitro and clinical data are inconsistent concerning the role of this enzyme in repaglinide elimination.	repaglinide	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	92-98
22296034-0	2012	NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.	repaglinide	86-97	neuronal differentiation 1	Homo sapiens	0-7
22296034-0	2012	NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.	repaglinide	86-97	paired box 4	Homo sapiens	17-21
22296034-1	2012	AIMS: We aimed to determine whether NeuroD1/BETA2 and PAX4 polymorphisms were associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetes mellitus (T2DM) patients.	repaglinide	122-133	neuronal differentiation 1	Homo sapiens	36-43
22296034-1	2012	AIMS: We aimed to determine whether NeuroD1/BETA2 and PAX4 polymorphisms were associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetes mellitus (T2DM) patients.	repaglinide	122-133	neuronal differentiation 1	Homo sapiens	44-49
22296034-1	2012	AIMS: We aimed to determine whether NeuroD1/BETA2 and PAX4 polymorphisms were associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetes mellitus (T2DM) patients.	repaglinide	122-133	paired box 4	Homo sapiens	54-58
22296034-10	2012	CONCLUSIONS: The NeuroD1/BETA2 and PAX4 polymorphisms were substantially associated with plasma glucose level after repaglinide monotherapy.	repaglinide	116-127	neuronal differentiation 1	Homo sapiens	17-24
22296034-10	2012	CONCLUSIONS: The NeuroD1/BETA2 and PAX4 polymorphisms were substantially associated with plasma glucose level after repaglinide monotherapy.	repaglinide	116-127	neuronal differentiation 1	Homo sapiens	25-30
22296034-10	2012	CONCLUSIONS: The NeuroD1/BETA2 and PAX4 polymorphisms were substantially associated with plasma glucose level after repaglinide monotherapy.	repaglinide	116-127	paired box 4	Homo sapiens	35-39
23153186-8	2012	The strong CYP2C8 and OATP1B1 inhibitor gemfibrozil increases substantially the plasma concentrations of repaglinide and TZDs.	repaglinide	105-116	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	11-17
23153186-8	2012	The strong CYP2C8 and OATP1B1 inhibitor gemfibrozil increases substantially the plasma concentrations of repaglinide and TZDs.	repaglinide	105-116	solute carrier organic anion transporter family member 1B1	Homo sapiens	22-29
22966882-0	2012	KCNQ1 variants and response to repaglinide treatment in patients with Type 2 diabetes.	repaglinide	31-42	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	0-5
22451699-9	2012	This systematic analysis revealed a comparable in vitro contribution from CYP2C8 and CYP3A4 to the metabolism of repaglinide (<50%), whereas the contribution of glucuronidation ranged from 2 to 20%, depending on the in vitro system used.	repaglinide	113-124	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
22451699-9	2012	This systematic analysis revealed a comparable in vitro contribution from CYP2C8 and CYP3A4 to the metabolism of repaglinide (<50%), whereas the contribution of glucuronidation ranged from 2 to 20%, depending on the in vitro system used.	repaglinide	113-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
22451699-10	2012	The repaglinide M4 metabolic pathway is proposed as a specific CYP2C8 probe for the assessment of drug-drug interactions.	repaglinide	4-15	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	63-69
22414228-0	2012	KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients.	repaglinide	73-84	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	0-5
24843581-1	2012	UNLABELLED: Aims/Introduction:  Repaglinide is a short-acting insulin secretagogue.	repaglinide	32-43	insulin	Homo sapiens	62-69
24843581-7	2012	The target HbA1c values of <6.9% were achieved by 75.0% of the repaglinide group vs 59.1% for nateglinide.	repaglinide	66-77	hemoglobin subunit alpha 1	Homo sapiens	11-15
22414228-1	2012	The present study evaluated the effects of KCNQ1 rs2237892 and rs2237895 polymorphisms on repaglinide efficacy in Chinese patients with type 2 diabetes mellitus (T2DM).	repaglinide	90-101	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	43-48
22414228-9	2012	In conclusion, KCNQ1 rs2237892 and rs2237895 polymorphisms were found to be associated with the therapeutic efficacy of repaglinide in Chinese T2DM patients.	repaglinide	120-131	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	15-20
22344703-3	2012	In this study, we have assessed the predictability of human PK for seven organic anion-transporting polypeptide (OATP) substrates (pravastatin, cerivastatin, bosentan, fluvastatin, rosuvastatin, valsartan, and repaglinide) for which clinical intravenous data were available.	repaglinide	210-221	solute carrier organic anion transporter family member 1A2	Homo sapiens	113-117
22083559-0	2012	Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.	repaglinide	77-88	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	18-24
22083559-6	2012	Kir and SUR were transiently coexpressed in HEK cells and [(3)H]glibenclamide binding and patch-clamp experiments were performed in whole cells at 37 C and in isolated inside/out patches at 22 C. Truncation of the first 5 N-terminal amino acids abolished most of the affinity increase for glibenclamide and repaglinide that is produced by the association of Kir6.2 with SUR1.	repaglinide	307-318	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	Homo sapiens	0-3
22424623-1	2012	OBJECTIVE: To investigate a potential relationship between Solute carrier family 30 (zinc transporter) member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients.	repaglinide	174-185	solute carrier family 30 member 8	Homo sapiens	59-111
22424623-1	2012	OBJECTIVE: To investigate a potential relationship between Solute carrier family 30 (zinc transporter) member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients.	repaglinide	174-185	solute carrier family 30 member 8	Homo sapiens	113-120
22424623-0	2012	Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.	repaglinide	61-72	solute carrier family 30 member 8	Homo sapiens	17-24
22393835-0	2012	Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.	repaglinide	50-61	uncoupling protein 2	Homo sapiens	34-38
21923736-12	2012	Tolbutamide and repaglinide may have partial pancreatic receptor selectivity because IC(50) values for SUR1 and SUR2A/SUR2B overlapped somewhat, with the C(SS) in the midst of these values.	repaglinide	16-27	ATP binding cassette subfamily C member 8	Homo sapiens	103-107
22210483-9	2012	Present study has raised the awareness of potential drug interactions by concomitant use of efonidipine with repaglinide, since efonidipine may alter the absorption and/or elimination of repaglinide by the inhibition of CYP3A4 and P-gp efflux pump.	repaglinide	109-120	phosphoglycolate phosphatase	Rattus norvegicus	231-235
22393835-1	2012	The aim of the present study was to evaluate the impact of the UCP2-866 G/A polymorphism on the efficacy of repaglinide in treating patients with diabetes mellitus type 2 (T2DM).	repaglinide	108-119	uncoupling protein 2	Homo sapiens	63-67
22393835-3	2012	16 patients with GG genotype, 14 with GA genotype and 11 with AA genotype of UCP2-866 G/A underwent an 8-week repaglinide treatment regimen.	repaglinide	110-121	uncoupling protein 2	Homo sapiens	77-81
22393835-6	2012	After repaglinide treatment for 8 consecutive weeks, we found that A allele carriers of UCP2 in the T2DM patients had smaller decrease in FPG (P < 0.05) and HbA1c (P < 0.05), and smaller increase in 30-min postload plasma insulin (P < 0.01) compared with GG genotypes.	repaglinide	6-17	uncoupling protein 2	Homo sapiens	88-92
22393835-7	2012	We demonstrated that UCP2-866 G/A polymorphism is associated with the therapeutic efficacy of repaglinide in Chinese T2DM patients.	repaglinide	94-105	uncoupling protein 2	Homo sapiens	21-25
22398664-0	2012	The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.	repaglinide	80-91	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
22398664-5	2012	RESULTS: The area under the plasma concentration-time curve from time 0 to infinity (AUC((0-inf))) of repaglinide was significantly higher in subjects possessing the MDR1 2677GT and 2677TT alleles than in those with the MDR1 2677GG and 2677TA alleles (p = 0.007).	repaglinide	102-113	ATP binding cassette subfamily B member 1	Homo sapiens	166-170
22398664-5	2012	RESULTS: The area under the plasma concentration-time curve from time 0 to infinity (AUC((0-inf))) of repaglinide was significantly higher in subjects possessing the MDR1 2677GT and 2677TT alleles than in those with the MDR1 2677GG and 2677TA alleles (p = 0.007).	repaglinide	102-113	ATP binding cassette subfamily B member 1	Homo sapiens	220-224
22398664-8	2012	CONCLUSION: This study shows that the genetic polymorphisms of MDR1 G2677T/A might explain the variability in the pharmacokinetics of repaglinide in the Chinese population.	repaglinide	134-145	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
21835486-6	2011	Repaglinide was also associated with an increase in the AUC(60) and AUC(120) for insulin (+56%, +61%) and C-peptide (+41%, +36%).	repaglinide	0-11	insulin	Homo sapiens	81-88
21835486-6	2011	Repaglinide was also associated with an increase in the AUC(60) and AUC(120) for insulin (+56%, +61%) and C-peptide (+41%, +36%).	repaglinide	0-11	insulin	Homo sapiens	106-115
21835486-9	2011	CONCLUSION: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release.	repaglinide	12-23	insulin	Homo sapiens	87-94
21835486-9	2011	CONCLUSION: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release.	repaglinide	12-23	insulin	Homo sapiens	99-108
21778352-0	2011	Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.	repaglinide	51-62	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	95-101
20598356-8	2011	SUR1 is selectively expressed in rat taste buds, and its distribution pattern may be functionally relevant, suggesting that the rapid insulin secretion-promoting effect of repaglinide may be exerted through the cephalic-phase secretion pathway mediated by taste buds.	repaglinide	172-183	ATP binding cassette subfamily C member 8	Rattus norvegicus	0-4
21477042-13	2011	Repaglinide had no effect on adipogenesis, although it causes insulin liberation like SUs.	repaglinide	0-11	insulin	Homo sapiens	62-69
21631570-0	2011	NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.	repaglinide	36-47	nicotinamide phosphoribosyltransferase	Homo sapiens	0-5
21631570-11	2011	The data suggest that the NAMPT -3186C>T polymorphism is significantly associated with plasma levels of PINS and CHO in Chinese T2DM patients with repaglinide monotherapy.	repaglinide	150-161	nicotinamide phosphoribosyltransferase	Homo sapiens	26-31
21590629-8	2011	Patients with MODY 3 were changed from insulin to repaglinide, those with MODY 2 were recommended discontinuing insulin treatment.	repaglinide	50-61	HNF1 homeobox A	Homo sapiens	14-20
21327909-0	2011	Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.	repaglinide	81-92	solute carrier organic anion transporter family member 1B1	Homo sapiens	11-18
21327909-2	2011	The objective of this research was to study the effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.	repaglinide	129-140	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-66
21327909-9	2011	CONCLUSIONS: SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC(0- ) and increased clearance of repaglinide.	repaglinide	137-148	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-20
21327909-9	2011	CONCLUSIONS: SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC(0- ) and increased clearance of repaglinide.	repaglinide	206-217	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-20
21327909-10	2011	Moreover, this polymorphism of SLCO1B1 has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.	repaglinide	92-103	solute carrier organic anion transporter family member 1B1	Homo sapiens	31-38
21362360-1	2011	BACKGROUND: Both repaglinide and gliclazide are insulin secretagogues widely used in the treatment of type 2 diabetes.	repaglinide	17-28	insulin	Homo sapiens	48-55
21270106-1	2011	The pharmacokinetics of repaglinide shows pronounced interindividual variability, for which several reasons have been considered, including interactions with drugs inhibiting CYP2C8 and CYP2C8 genetic polymorphism.	repaglinide	24-35	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	186-192
21270106-3	2011	We studied the effect of CYP2C8*3 on the pharmacokinetics and pharmacodynamics of repaglinide in 29 healthy whites carrying CYP2C8*3/*3 (n = 4), CYP2C8*1/*3 (n = 13), or CYP2C8*1/*1 (n = 12).	repaglinide	82-93	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	25-31
21289621-5	2011	Our results indicated that KCNQ1 polymorphisms are associated with repaglinide efficacy, and might also be associated with rosiglitazone response, in Chinese patients with type 2 diabetes.	repaglinide	67-78	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	27-32
21175273-0	2011	Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.	repaglinide	10-21	insulin	Homo sapiens	67-74
21175273-1	2011	BACKGROUND: studies in younger patients with diabetes have shown that insulin profiles are more physiologic and postprandial glucose levels are lower with repaglinide than with glyburide.	repaglinide	155-166	insulin	Homo sapiens	70-77
21175273-5	2011	RESULTS: the 0-30 min area under the curve (AUC) for insulin was higher (glyburide, 294  +-  37 pM; repaglinide, 382  +-  39 pM) (P < 0.01), and the 180-240 min AUC for insulin was lower (glyburide, 325  +-  50 pM; repaglinide, 196 +- 20 pM) (P < 0.01) with repaglinide.	repaglinide	100-111	insulin	Homo sapiens	53-60
21175273-5	2011	RESULTS: the 0-30 min area under the curve (AUC) for insulin was higher (glyburide, 294  +-  37 pM; repaglinide, 382  +-  39 pM) (P < 0.01), and the 180-240 min AUC for insulin was lower (glyburide, 325  +-  50 pM; repaglinide, 196 +- 20 pM) (P < 0.01) with repaglinide.	repaglinide	218-229	insulin	Homo sapiens	53-60
21175273-5	2011	RESULTS: the 0-30 min area under the curve (AUC) for insulin was higher (glyburide, 294  +-  37 pM; repaglinide, 382  +-  39 pM) (P < 0.01), and the 180-240 min AUC for insulin was lower (glyburide, 325  +-  50 pM; repaglinide, 196 +- 20 pM) (P < 0.01) with repaglinide.	repaglinide	218-229	insulin	Homo sapiens	53-60
21175273-8	2011	CONCLUSIONS: we conclude that repaglinide results in a more physiologic insulin profile and less frequent hypoglycemia than glyburide in the elderly.	repaglinide	30-41	insulin	Homo sapiens	72-79
21270106-0	2011	Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.	repaglinide	78-89	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	14-20
21270106-1	2011	The pharmacokinetics of repaglinide shows pronounced interindividual variability, for which several reasons have been considered, including interactions with drugs inhibiting CYP2C8 and CYP2C8 genetic polymorphism.	repaglinide	24-35	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	175-181
21362360-9	2011	The maximum insulin concentration occurred earlier in the repaglinide group than that in the gliclazide group.	repaglinide	58-69	insulin	Homo sapiens	12-19
30861688-3	2010	Repaglinide, a rapidly acting insulin secretagog, stimulates insulin secretion via closure of ATP-dependent potassium channels on the cell membrane of beta-cells.	repaglinide	0-11	insulin	Homo sapiens	30-37
21548456-1	2011	Meglitinides (repaglinide and nateglinide) are insulin secretagogues used to treat diabetes mellitus.	repaglinide	14-25	insulin	Homo sapiens	47-54
22086064-9	2011	In mice challenged systemically or intratracheally with LPS, repaglinide significantly decreased serum tumor necrosis factor alpha level and bronchial alveolar lavage fluid MCP-1 levels, respectively.	repaglinide	61-72	tumor necrosis factor	Mus musculus	103-130
22086064-9	2011	In mice challenged systemically or intratracheally with LPS, repaglinide significantly decreased serum tumor necrosis factor alpha level and bronchial alveolar lavage fluid MCP-1 levels, respectively.	repaglinide	61-72	mast cell protease 1	Mus musculus	173-178
22041697-3	2011	Organic anion transporting polypeptide 1B1 (OATP1B1, gene SLCO1B1) is expressed on the basolateral membrane of hepatocytes and can facilitate hepatic uptake of certain clinically relevant drugs such as statins except for fluvastatin, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, antidiabetic drug (repaglinide) and anticancer drugs (SN-38 and methotrexate).	repaglinide	332-343	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-42
22041697-3	2011	Organic anion transporting polypeptide 1B1 (OATP1B1, gene SLCO1B1) is expressed on the basolateral membrane of hepatocytes and can facilitate hepatic uptake of certain clinically relevant drugs such as statins except for fluvastatin, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, antidiabetic drug (repaglinide) and anticancer drugs (SN-38 and methotrexate).	repaglinide	332-343	solute carrier organic anion transporter family member 1B1	Homo sapiens	44-51
22041697-3	2011	Organic anion transporting polypeptide 1B1 (OATP1B1, gene SLCO1B1) is expressed on the basolateral membrane of hepatocytes and can facilitate hepatic uptake of certain clinically relevant drugs such as statins except for fluvastatin, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, antidiabetic drug (repaglinide) and anticancer drugs (SN-38 and methotrexate).	repaglinide	332-343	solute carrier organic anion transporter family member 1B1	Homo sapiens	58-65
20809084-0	2010	Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.	repaglinide	106-117	solute carrier family 30 member 8	Homo sapiens	24-31
20809084-2	2010	This study aimed to investigate whether the SLC30A8 rs13266634 and rs16889462 polymorphisms were associated with T2DM susceptibility and repaglinide therapeutic efficacy in Chinese T2DM patients.	repaglinide	137-148	solute carrier family 30 member 8	Homo sapiens	44-51
20809084-9	2010	CONCLUSIONS: SLC30A8 rs13266634 and rs16889462 polymorphisms were associated with repaglinide therapeutic efficacy in Chinese T2DM patients.	repaglinide	82-93	solute carrier family 30 member 8	Homo sapiens	13-20
20406215-5	2010	The SLCO1B1 c.521CC genotype has been associated with an about 60-190% increased, and the SLCO1B1*1B/*1B genotype with an about 30% decreased area under the plasma concentration-time curve of repaglinide.	repaglinide	192-203	solute carrier organic anion transporter family member 1B1	Homo sapiens	4-11
20406215-5	2010	The SLCO1B1 c.521CC genotype has been associated with an about 60-190% increased, and the SLCO1B1*1B/*1B genotype with an about 30% decreased area under the plasma concentration-time curve of repaglinide.	repaglinide	192-203	solute carrier organic anion transporter family member 1B1	Homo sapiens	90-97
20406215-6	2010	Moreover, SLCO1B1 polymorphism can affect the extent of interaction between OATP1B1 inhibitors and repaglinide.	repaglinide	99-110	solute carrier organic anion transporter family member 1B1	Homo sapiens	10-17
20406215-6	2010	Moreover, SLCO1B1 polymorphism can affect the extent of interaction between OATP1B1 inhibitors and repaglinide.	repaglinide	99-110	solute carrier organic anion transporter family member 1B1	Homo sapiens	76-83
20406215-7	2010	Accordingly, SLCO1B1 genotyping may help in choosing the optimal starting dose of repaglinide.	repaglinide	82-93	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-20
21175442-4	2010	Finally, a panel of human liver microsomes (genotyped for UGT1A1*28 allele status) was used to determine the importance of UGT1A1 in the direct glucuronidation of repaglinide.	repaglinide	163-174	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	123-129
21175442-10	2010	UGT1A1 plays a significant role in the glucuronidation of repaglinide.	repaglinide	58-69	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
21175442-12	2010	CONCLUSIONS: Inhibition of UGT enzymes, especially UGT1A1, by gemfibrozil and its glucuronide is an additional mechanism to consider when rationalizing the interaction between repaglinide and gemfibrozil.	repaglinide	176-187	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	27-30
21175442-12	2010	CONCLUSIONS: Inhibition of UGT enzymes, especially UGT1A1, by gemfibrozil and its glucuronide is an additional mechanism to consider when rationalizing the interaction between repaglinide and gemfibrozil.	repaglinide	176-187	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	51-57
20523342-0	2010	IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.	repaglinide	29-40	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	0-7
20523342-8	2010	CONCLUSION: The IGF2BP2 rs1470579 and rs4402960 polymorphisms may be associated with the development of T2DM, and these polymorphisms may affect the therapeutic efficacy of repaglinide in Chinese T2DM patients.	repaglinide	173-184	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	16-23
30861688-3	2010	Repaglinide, a rapidly acting insulin secretagog, stimulates insulin secretion via closure of ATP-dependent potassium channels on the cell membrane of beta-cells.	repaglinide	0-11	insulin	Homo sapiens	61-68
20305679-0	2010	A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.	repaglinide	46-57	nitric oxide synthase 1 adaptor protein	Homo sapiens	15-21
20305679-0	2010	A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.	repaglinide	46-57	insulin	Homo sapiens	70-77
20305679-1	2010	AIM: To investigate a potential association between SNP rs10494366 in the neural nitric oxide synthase adaptor protein (NOS1AP) and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetes patients.	repaglinide	144-155	nitric oxide synthase 1 adaptor protein	Homo sapiens	120-126
20305679-1	2010	AIM: To investigate a potential association between SNP rs10494366 in the neural nitric oxide synthase adaptor protein (NOS1AP) and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetes patients.	repaglinide	144-155	insulin	Homo sapiens	160-167
20305679-7	2010	After 24-week repaglinide monotherapy, the Delta value of fasting insulin (P=0.019) and HOMA-IR (P=0.011) were significantly different.	repaglinide	14-25	insulin	Homo sapiens	66-73
20305679-10	2010	CONCLUSION: A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients.	repaglinide	62-73	insulin	Homo sapiens	98-105
19900993-1	2009	OBJECTIVES: To study the effect of insulin treatment in combination with metformin or an insulin secretagogue, repaglinide, on glycaemic regulation in non-obese patients with type 2 diabetes.	repaglinide	111-122	insulin	Homo sapiens	89-96
19940232-7	2010	Def erasirox caused increases in repaglinide plasma C(max) and AUC of 1.5-fold to over 2-fold, respectively, with little change in blood glucose measures.	repaglinide	33-44	UTP25 small subunit processome component	Homo sapiens	0-3
20197475-8	2010	Trimethoprim induced CYP2C8 inhibition, thus increasing the plasma concentration of repaglinide.	repaglinide	84-95	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
20197475-14	2010	CONCLUSIONS: This interaction between TMP/SMX and repaglinide may have involved inhibition of CYP2C8 by trimethoprim.	repaglinide	50-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	94-100
20054294-0	2010	KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.	repaglinide	86-97	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	0-6
20054294-0	2010	KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.	repaglinide	86-97	transcription factor 7 like 2	Homo sapiens	20-26
20054294-9	2010	The KCNJ11 and TCF7L2 polymorphisms were associated with repaglinide efficacy.	repaglinide	57-68	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	4-10
20054294-9	2010	The KCNJ11 and TCF7L2 polymorphisms were associated with repaglinide efficacy.	repaglinide	57-68	transcription factor 7 like 2	Homo sapiens	15-21
20523106-0	2010	CYP3A4 genetic polymorphism influences repaglinide"s pharmacokinetics.	repaglinide	39-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
20523106-1	2010	AIM: To investigate the effects of CYP3A4 and CYP2C8 enzymes on repaglinide"s pharmacokinetics in healthy Malaysian subjects.	repaglinide	64-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
20523106-1	2010	AIM: To investigate the effects of CYP3A4 and CYP2C8 enzymes on repaglinide"s pharmacokinetics in healthy Malaysian subjects.	repaglinide	64-75	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	46-52
20523106-8	2010	However, the CYP3A4 genotype significantly influenced some of repaglinide"s pharmacokinetics, where the mean elimination rate constant was 44.0% lower (p = 0.04) and the mean half-life was 33.8% higher (p = 0.04) in subjects with the CYP3A4*1/*18 genotype as compared to those with the normal CYP3A4*1/*1 genotype.	repaglinide	62-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
20523106-8	2010	However, the CYP3A4 genotype significantly influenced some of repaglinide"s pharmacokinetics, where the mean elimination rate constant was 44.0% lower (p = 0.04) and the mean half-life was 33.8% higher (p = 0.04) in subjects with the CYP3A4*1/*18 genotype as compared to those with the normal CYP3A4*1/*1 genotype.	repaglinide	62-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	234-240
20523106-8	2010	However, the CYP3A4 genotype significantly influenced some of repaglinide"s pharmacokinetics, where the mean elimination rate constant was 44.0% lower (p = 0.04) and the mean half-life was 33.8% higher (p = 0.04) in subjects with the CYP3A4*1/*18 genotype as compared to those with the normal CYP3A4*1/*1 genotype.	repaglinide	62-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	234-240
20523106-9	2010	This result confirms that CYP3A4 plays a large role in metabolizing repaglinide.	repaglinide	68-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
20523106-10	2010	CONCLUSION: Genetic polymorphisms of CYP3A4, specifically CYP3A4*18, play a major role in contributing to the interindividual variability in repaglinide"s pharmacokinetics.	repaglinide	141-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
20523106-10	2010	CONCLUSION: Genetic polymorphisms of CYP3A4, specifically CYP3A4*18, play a major role in contributing to the interindividual variability in repaglinide"s pharmacokinetics.	repaglinide	141-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
19761371-5	2009	Contrary to in vitro data, clinical data suggest that the CYP2C8*3 allele is associated with increased metabolism of the CYP2C8 substrates, rosiglitazone, pioglitazone and repaglinide.	repaglinide	172-183	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	58-64
19785645-9	2009	SLCO1B1 polymorphism also affects the pharmacokinetics of many other, but not all (fluvastatin), statins and that of the antidiabetic drug repaglinide, the antihistamine fexofenadine and the endothelin A receptor antagonist atrasentan.	repaglinide	139-150	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
19531054-1	2009	AIM: To assess the efficacy and safety of a new repaglinide/metformin fixed-dose combination (FDC) tablet administered either twice a day (BID) or three times a day (TID) for the management of type 2 diabetes.	repaglinide	48-59	BH3 interacting domain death agonist	Homo sapiens	139-142
19761371-5	2009	Contrary to in vitro data, clinical data suggest that the CYP2C8*3 allele is associated with increased metabolism of the CYP2C8 substrates, rosiglitazone, pioglitazone and repaglinide.	repaglinide	172-183	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	121-127
19476470-6	2009	Reductions in HbA1c values became apparent at earlier times for repaglinide/metformin FDC BID treatment than rosiglitazone/metformin FDC BID, and final changes in HbA1c were not significantly different between treatment arms (p = 0.8186); thus, the predefined statistical criterion for non-inferiority was met.	repaglinide	64-75	BH3 interacting domain death agonist	Homo sapiens	90-93
19476470-9	2009	Thus, repaglinide/metformin FDC BID is a clinically feasible alternative to rosiglitazone/metformin FDC BID.	repaglinide	6-17	BH3 interacting domain death agonist	Homo sapiens	32-35
19754390-9	2009	Glinides (repaglinide and nateglinide) have also been documented to improve endothelial function and lipid profile, to reduce oxidative stress, platelet activity and inflammatory markers, and to diminish the progression of CIMT.	repaglinide	10-21	CIMT	Homo sapiens	223-227
21437123-3	2009	Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin sensitizer, targets FBG.	repaglinide	0-11	insulin	Homo sapiens	28-35
18777156-6	2009	During the repaglinide treatment, the meal related peaks of C-peptide and free human insulin were about twofold higher than during treatment with insulin aspart.	repaglinide	11-22	insulin	Homo sapiens	60-69
18777156-6	2009	During the repaglinide treatment, the meal related peaks of C-peptide and free human insulin were about twofold higher than during treatment with insulin aspart.	repaglinide	11-22	insulin	Homo sapiens	85-92
18777156-6	2009	During the repaglinide treatment, the meal related peaks of C-peptide and free human insulin were about twofold higher than during treatment with insulin aspart.	repaglinide	11-22	insulin	Homo sapiens	146-153
18777156-7	2009	Proinsulin, GHBP were higher and IAPP levels tended to be higher during repaglinide compared to insulin aspart.	repaglinide	72-83	islet amyloid polypeptide	Homo sapiens	33-37
18777156-8	2009	Postprandial plasma total cholesterol, triglycerides and apolipoprotein B concentrations were higher on repaglinide than on insulin aspart treatment.	repaglinide	104-115	apolipoprotein B	Homo sapiens	57-73
18777156-9	2009	Our results show that, at the same glycemic control, treatment with exogenous insulin aspart in comparison with the insulin secretagogue repaglinide result in a lower endogenous insulin secretion, and a tendency towards a less atherogenic postprandial lipid profile.	repaglinide	137-148	insulin	Homo sapiens	116-123
18777156-1	2009	Our aim was to study, at the same glycemic control, how treatment with either the insulin secretagogue repaglinide or exogenous insulin aspart affects endogenous insulin secretion, plasma insulin and IAPP (islet amyloid polypeptide) levels, GH-IGF (growth hormone-insulin-like growth factor) axis and plasma lipoprotein concentrations in patients with type 2 diabetes.	repaglinide	103-114	insulin	Homo sapiens	82-89
18777156-1	2009	Our aim was to study, at the same glycemic control, how treatment with either the insulin secretagogue repaglinide or exogenous insulin aspart affects endogenous insulin secretion, plasma insulin and IAPP (islet amyloid polypeptide) levels, GH-IGF (growth hormone-insulin-like growth factor) axis and plasma lipoprotein concentrations in patients with type 2 diabetes.	repaglinide	103-114	islet amyloid polypeptide	Homo sapiens	200-204
19232035-2	2009	The primary endpoint of the study was to evaluate which add-on treatment between acarbose and repaglinide is more efficacious in reducing PPG.	repaglinide	94-105	serglycin	Homo sapiens	138-141
19232035-8	2009	After 15 weeks of therapy, the repaglinide-treated patients experienced a significant decrease in HbA(1c) (-1.1%, p < 0.05), FPG (-9.5%, p < 0.05), and PPG (-14.9%, p < 0.05), when compared to the baseline values.	repaglinide	31-42	serglycin	Homo sapiens	158-161
18844675-0	2008	Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin.	repaglinide	42-53	albumin	Homo sapiens	81-94
18854776-0	2008	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.	repaglinide	84-95	solute carrier organic anion transporter family member 1B1	Homo sapiens	15-22
18854776-2	2008	The aim of this study was to investigate whether the SLCO1B1*1B haplotype affects the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.	repaglinide	127-138	solute carrier organic anion transporter family member 1B1	Homo sapiens	53-60
18854776-4	2008	Plasma repaglinide and nateglinide and blood glucose concentrations were measured for 7 h. RESULTS: The AUC(0-infinity) and Cmax of repaglinide were 32% (P=0.007) and 24% lower (P=0.056) in the individuals with the SLCO1B1*1B/*1B genotype than in those with the SLCO1B1*1A/*1A genotype.	repaglinide	132-143	solute carrier organic anion transporter family member 1B1	Homo sapiens	215-222
18854776-4	2008	Plasma repaglinide and nateglinide and blood glucose concentrations were measured for 7 h. RESULTS: The AUC(0-infinity) and Cmax of repaglinide were 32% (P=0.007) and 24% lower (P=0.056) in the individuals with the SLCO1B1*1B/*1B genotype than in those with the SLCO1B1*1A/*1A genotype.	repaglinide	132-143	solute carrier organic anion transporter family member 1B1	Homo sapiens	262-269
18854776-5	2008	The mean blood glucose concentration from 0 to 7 h after repaglinide intake was 10% higher in the SLCO1B1*1B/*1B participants than in the SLCO1B1*1A/*1A participants (P=0.007).	repaglinide	57-68	solute carrier organic anion transporter family member 1B1	Homo sapiens	98-105
18854776-5	2008	The mean blood glucose concentration from 0 to 7 h after repaglinide intake was 10% higher in the SLCO1B1*1B/*1B participants than in the SLCO1B1*1A/*1A participants (P=0.007).	repaglinide	57-68	solute carrier organic anion transporter family member 1B1	Homo sapiens	138-145
18854776-7	2008	CONCLUSION: The SLCO1B1*1B/*1B genotype is associated with reduced plasma concentrations of repaglinide, consistent with an enhanced hepatic uptake by OATP1B1, but has limited effects on the pharmacokinetics of nateglinide.	repaglinide	92-103	solute carrier organic anion transporter family member 1B1	Homo sapiens	16-23
20409940-6	2009	The sulfonylurea ligands tolbutamide and repaglinide, but not glibenclamide, increased stretch-promoted ANF secretion.	repaglinide	41-52	natriuretic peptide A	Rattus norvegicus	104-107
18823304-0	2008	The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.	repaglinide	38-49	solute carrier organic anion transporter family member 1B1	Homo sapiens	14-21
18823304-3	2008	RESULTS: The mean area under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) of 0.25, 0.5, 1 or 2 mg repaglinide was 82% (95% confidence interval 47, 125), 72% (24, 138), 56% (24, 95) or 108% (59, 171) (P < or = 0.001) larger in participants with the SLCO1B1 c.521CC genotype than in those with the c.521TT genotype, respectively.	repaglinide	131-142	solute carrier organic anion transporter family member 1B1	Homo sapiens	284-291
18823304-6	2008	CONCLUSIONS: The effect of SLCO1B1 c.521T-->C polymorphism on the pharmacokinetics of repaglinide persists throughout the clinically relevant dose range.	repaglinide	89-100	solute carrier organic anion transporter family member 1B1	Homo sapiens	27-34
18844675-1	2008	Mechanism of interaction of antidiabetic drugs, repaglinide and gliclazide, to human serum albumin has been studied using fluorescence spectroscopic technique.	repaglinide	48-59	albumin	Homo sapiens	85-98
18844675-2	2008	Repaglinide had much higher affinity for human serum albumin when compared with gliclazide.	repaglinide	0-11	albumin	Homo sapiens	47-60
18844675-8	2008	Repaglinide and gliclazide are bound to site II on the human serum albumin molecule, and the aromatic ring of 411Tyr appears to be involved in binding within site II.	repaglinide	0-11	albumin	Homo sapiens	61-74
18187595-0	2008	Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.	repaglinide	90-101	solute carrier organic anion transporter family member 1B1	Homo sapiens	21-28
19238654-0	2008	Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.	repaglinide	67-78	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-101
19238654-2	2008	The mean increase in the repaglinide area under the plasma concentration-time curve from 0 h to infinity (AUC(0-infinity)) produced by gemfibrozil was larger in individuals with the SLCO1B1 c.521CC genotype (n = 6) than in those with the c.521TC (n = 6) and c.521TT (n = 12) genotypes, by factors of 1.56 (P = 0.004) and 1.54 (P = 0.002), respectively.	repaglinide	25-36	solute carrier organic anion transporter family member 1B1	Homo sapiens	182-189
19238654-6	2008	In conclusion, the extent of gemfibrozil-repaglinide interaction depends on SLCO1B1 genotype.	repaglinide	41-52	solute carrier organic anion transporter family member 1B1	Homo sapiens	76-83
19238654-7	2008	Atorvastatin raises plasma repaglinide concentrations, probably by inhibiting organic anion transporting polypeptide 1B1 (OATP1B1).	repaglinide	27-38	solute carrier organic anion transporter family member 1B1	Homo sapiens	78-120
19238654-7	2008	Atorvastatin raises plasma repaglinide concentrations, probably by inhibiting organic anion transporting polypeptide 1B1 (OATP1B1).	repaglinide	27-38	solute carrier organic anion transporter family member 1B1	Homo sapiens	122-129
18664331-0	2008	Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.	repaglinide	71-82	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	15-21
18664331-0	2008	Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.	repaglinide	71-82	ATP binding cassette subfamily C member 8	Homo sapiens	26-31
18664331-1	2008	AIM: The aim of this study was to investigate the association of KCNJ11 E23K and ABCC8 exon16-3T/C with the therapeutic effect of repaglinide in patients with type 2 diabetes.	repaglinide	130-141	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	65-71
18664331-1	2008	AIM: The aim of this study was to investigate the association of KCNJ11 E23K and ABCC8 exon16-3T/C with the therapeutic effect of repaglinide in patients with type 2 diabetes.	repaglinide	130-141	ATP binding cassette subfamily C member 8	Homo sapiens	81-86
18664331-10	2008	CONCLUSION: The KCNJ11 E23K variant was associated with the therapeutic effect of repaglinide.	repaglinide	82-93	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	16-22
18664331-11	2008	In addition, The C/C homozygotes of the ABCC8 exon16-3T/C variant responded better to repaglinide in insulin sensitivity than the T/C and T/T genotypes.	repaglinide	86-97	ATP binding cassette subfamily C member 8	Homo sapiens	40-45
18664331-11	2008	In addition, The C/C homozygotes of the ABCC8 exon16-3T/C variant responded better to repaglinide in insulin sensitivity than the T/C and T/T genotypes.	repaglinide	86-97	insulin	Homo sapiens	101-108
17923851-0	2008	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.	repaglinide	85-96	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	26-32
17923851-4	2008	In healthy white subjects, CYP2C8*3 and the two novel haplotypes significantly influenced repaglinide pharmacokinetics in SLCO1B1c.521T/C heterozygous individuals: haplotype B was associated with reduced and haplotype C with increased repaglinide AUC (0-infinity).	repaglinide	90-101	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	27-33
17923851-4	2008	In healthy white subjects, CYP2C8*3 and the two novel haplotypes significantly influenced repaglinide pharmacokinetics in SLCO1B1c.521T/C heterozygous individuals: haplotype B was associated with reduced and haplotype C with increased repaglinide AUC (0-infinity).	repaglinide	90-101	solute carrier organic anion transporter family member 1B1	Homo sapiens	122-129
18314419-6	2008	However, OATP-mediated BSP and pravastatin uptake and OCT1-mediated MPP(+) and metformin uptake were significantly inhibited by repaglinide (half-maximal inhibitory concentration [IC(50)] 1.6-5.6 micromol/l) and rosiglitazone (IC(50) 5.2-30.4 micromol/l).	repaglinide	128-139	solute carrier organic anion transporter family member 1A2	Homo sapiens	9-13
18314419-6	2008	However, OATP-mediated BSP and pravastatin uptake and OCT1-mediated MPP(+) and metformin uptake were significantly inhibited by repaglinide (half-maximal inhibitory concentration [IC(50)] 1.6-5.6 micromol/l) and rosiglitazone (IC(50) 5.2-30.4 micromol/l).	repaglinide	128-139	solute carrier family 22 member 1	Homo sapiens	54-58
18505128-6	2008	RESULTS: Similar decreases in fasting blood glucose, 2 hours postprandial blood glucose, and HbA1 c were found in both nateglinide group and repaglinide group without significant differences.	repaglinide	141-152	hemoglobin subunit alpha 1	Homo sapiens	93-97
18621529-4	2008	Furthermore, (2R,3R,4S)-hydantoin stimulates the insulin secretion by 150% at 25microM compared with 4-hydroxyisoleucine and insulin secretagogue drug repaglinide.	repaglinide	151-162	insulin	Homo sapiens	125-132
18187595-2	2008	Participants with SLCO1B1 c.521CC genotype (n = 4) had a 59% (P = 0.001) or 72% (P < 0.001) greater mean area under the plasma repaglinide concentration-time curve (AUC(0-infinity)) than participants with c.521TC (n = 12) or c.521TT (n = 16) genotypes.	repaglinide	130-141	solute carrier organic anion transporter family member 1B1	Homo sapiens	18-25
17587398-0	2007	Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.	repaglinide	77-88	insulin	Homo sapiens	15-22
18166815-9	2008	In contrast, fasting levels and AUC of total cholesterol, low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (non-HDL) cholesterol and serum insulin were lower during metformin than repaglinide (mean (95% confidence intervals), LDL cholesterol difference metformin versus repaglinide: AUC: -0.17 mmol/l (-0.26; -0.08)).	repaglinide	203-214	insulin	Homo sapiens	162-169
18166815-9	2008	In contrast, fasting levels and AUC of total cholesterol, low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (non-HDL) cholesterol and serum insulin were lower during metformin than repaglinide (mean (95% confidence intervals), LDL cholesterol difference metformin versus repaglinide: AUC: -0.17 mmol/l (-0.26; -0.08)).	repaglinide	293-304	insulin	Homo sapiens	162-169
17712875-12	2007	A mixed model analysis of variance on the 178 patients who started with combination therapy, either immediately or after a 3-6 month period on diet, showed that metformin plus gliclazide, repaglinide, or pioglitazone was associated with a gradual increase in HbA1c values.	repaglinide	188-199	hemoglobin subunit alpha 1	Homo sapiens	259-263
17587398-16	2007	CONCLUSIONS: The efficacy of repaglinide and nateglinide in FBG, postprandial glucose excursion and early-phase insulin secretion is similar.	repaglinide	29-40	insulin	Homo sapiens	112-119
17587398-19	2007	This trial had shown that nateglinide and repaglinide could comparably improve insulin sensitivity and beta-cell function.	repaglinide	42-53	insulin	Homo sapiens	79-86